Company Quick10K Filing
Quick10K
American Shared Hospital Services
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$2.68 6 $15
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2018-11-08 Earnings, Exhibits
8-K 2018-09-27 Regulation FD, Exhibits
8-K 2018-08-09 Earnings, Exhibits
8-K 2018-06-14 Shareholder Vote
8-K 2018-03-26 Earnings, Exhibits
MXIM Maxim Integrated Products 16,370
NBL Noble Energy 13,110
ICL Israel Chemicals 6,980
POOL Pool 6,760
NBEV New Age Beverages 392
MCB Metropolitan Bank Holding 306
GSIT GSI Technology 173
NBY Novabay Pharmaceuticals 19
TWMC Trans World Entertainment 11
FPNI Fraud Protection Network 0
AMS 2018-12-31
Part I
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
Part II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6. Selected Financial Data
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
Part III
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accounting Fees and Services
Part IV
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10-K Summary
Note 1 - Business and Basis of Presentation
Note 2 - Accounting Policies
Note 3 - Property and Equipment
Note 4 - Investment in Equity Securities
Note 5 - Long-Term Debt
Note 6 - Obligations Under Capital Leases
Note 7 - Income Taxes
Note 8 - Shareholders' Equity
Note 9 - Retirement Plan
Note 10 - Operating Leases
Note 11 - Commitments and Contingencies
Note 12 - Note, Warrant, & Common Stock Purchase Agreement with Related Parties
Note 13 -Related Party Transactions
EX-21.1 tv516904_ex21-1.htm
EX-23.1 tv516904_ex23-1.htm
EX-31.1 tv516904_ex31-1.htm
EX-31.2 tv516904_ex31-2.htm
EX-32.1 tv516904_ex32-1.htm

American Shared Hospital Services Earnings 2018-12-31

AMS 10K Annual Report

Balance SheetIncome StatementCash Flow

10-K 1 tv516904_10k.htm FORM 10-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

____________________

 

FORM 10-K

(Mark One)

 

x Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act of 1934
  For The Fiscal Year Ended December 31, 2018

 

or

 

¨ Transition Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act of 1934
  For The Transition Period From _______________ to _______________ .

 

Commission file number 1-08789

____________________

 

American Shared Hospital Services

(Exact name of registrant as specified in its charter)

 

California   94-2918118
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

Two Embarcadero Center, Suite 410, San Francisco, California   94111-4107
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (415) 788-5300

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Name of each exchange on which registered
Common Stock No Par Value   NYSE AMERICAN

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ¨ No x

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

  

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ¨ Accelerated Filer ¨ Non-accelerated Filer x Smaller reporting company x
      Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

 

As of June 30, 2018, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $10,027,000.

 

Number of shares of common stock of the registrant outstanding as of March 20, 2019: 5,714,000.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive Proxy Statement for the 2018 Annual Meeting of Shareholders are incorporated by reference into Part III of this report.

  

 

 

 

 

 

TABLE OF CONTENTS   Page
     
FORWARD-LOOKING STATEMENTS    
     
PART I:        
         
Item 1   Business   4
         
Item 1A   Risk Factors   12
         
Item 1B   Unresolved Staff Comments   15
         
Item 2   Properties   15
         
Item 3   Legal Proceedings   15
         
Item 4   Mine Safety Disclosures   15
         
PART II:        
         
Item 5   Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   15
         
Item 6   Selected Financial Data   17
         
Item 7   Management’s Discussion and Analysis of Financial Condition  and Results of Operations   18
         
Item 7A   Quantitative and Qualitative Disclosure about Market Risk   27
         
Item 8   Financial Statements and Supplementary Data   27
         
Item 9   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure   28
         
Item 9A   Controls and Procedures   28
         
Item 9B   Other Information   28
         
PART III:        
         
Item 10   Directors, Executive Officers and Corporate Governance   28
         
Item 11   Executive Compensation   29
         
Item 12   Security Ownership of Certain Beneficial Owners and Management  and Related Stockholder Matters   29
         
Item 13   Certain Relationships and Related Transactions, and Director Independence   29
         
Item 14   Principal Accountant Fees and Services   29
         
PART IV:        
         
Item 15   Exhibits and Financial Statement Schedules   29
         
Item 16   Form 10-K Summary   40

 

2

 

 

FORWARD-LOOKING STATEMENTS

 

Certain matters discussed in this Annual Report on Form 10-K other than statements of historical information are “forward-looking statements.” The Private Securities Litigation Reform Act of 1995 has established that these statements qualify for safe harbors from liability. Forward-looking statements may include words like we “believe”, “anticipate”, “target”, “expect”, “pro forma”, “estimate”, “intend”, “will”, “is designed to”, “plan” and words of similar meaning. Forward-looking statements describe our future plans, objectives, expectations or goals. Such statements address future events and conditions concerning and include, but are not limited to, such things as:

 

·capital expenditures
·earnings
·liquidity and capital resources
·financing of our business
·government programs and regulations
·legislation affecting the health care industry
·the expansion of our proton beam radiation therapy business
·accounting matters
·compliance with debt covenants
·competition
·customer concentration
·contractual obligations
·timing of payments
·technology
·interest rates

 

These forward-looking statements involve known and unknown risks that may cause our actual results in future periods to differ materially from those expressed in any forward-looking statement. Factors that could cause or contribute to such differences include, but are not limited to, such things as:

 

·our high level of debt
·the limited market for our capital-intensive services
·the impact of lowered federal reimbursement rates
·the impact of recent U.S. health care reform legislation
·competition and alternatives to our services
·technological advances and the risk of equipment obsolescence
·our significant investment in the proton beam radiation therapy business
·the small and illiquid market for our stock

 

These lists are not all-inclusive because it is not possible to predict all factors. A discussion of some of these factors is included in this document under the headings “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” “–Application of Critical Accounting Policies” and “–Liquidity and Capital Resources.” This report should be read in its entirety. No one section of this report deals with all aspects of the subject matter. Any forward-looking statement speaks only as of the date such statement was made, and we are not obligated to update any forward-looking statement to reflect events or circumstances after the date on which such statement was made, except as required by applicable laws or regulations.

 

3

 

 

PART I

 

ITEM 1. BUSINESS

 

GENERAL

 

American Shared Hospital Services (“ASHS” and, together with its subsidiaries, the “Company”) provides Gamma Knife stereotactic radiosurgery equipment and radiation therapy and related equipment to sixteen (16) medical centers in fourteen (14) states in the United States and one Gamma Knife unit at a stand-alone facility in Lima, Peru as of March 1, 2019. The Company provides Gamma Knife services through its 81% indirect interest in GK Financing, LLC, a California limited liability company (“GKF”). The remaining 19% of GKF is owned by GKV Investments, Inc., a wholly-owned U.S. subsidiary of Elekta AG, a Swedish company (“Elekta”). Elekta is the manufacturer of the Leksell Gamma Knifeâ (the “Gamma Knife”). GKF is a non-exclusive provider of alternative financing services for Leksell Gamma Knife units.

 

The Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), OR21, Inc. and MedLeader.com, Inc. (“MedLeader”). ASRS is the majority-owner of GKF.

 

GKF has established the wholly-owned subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) for the purpose of providing similar Gamma Knife services in Peru.

 

GKF also owns a 51% interest in Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The remaining 49% in each of these two companies is owned by radiation oncologists.

 

The Company is also the sole owner of PBRT Orlando, LLC (“Orlando”) and the majority owner of Long Beach Equipment, LLC (“LBE”) which were formed to provide proton beam radiation therapy services in Orlando, Florida and Long Beach, California. A 40% minority ownership in LBE is owned by radiation oncologists.

 

The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM through its 50% owned OR21, LLC (“OR21”). The remaining 50% of OR21 is owned by an architectural design company. OR21 is not expected to generate significant revenue within the next two years.

 

The Company was incorporated in the State of California in 1983 and its predecessor, Ernest A. Bates, M.D., Ltd. (d/b/a American Shared Hospital Services), a California limited partnership, was formed in June 1980.

 

OPERATIONS

 

Gamma Knife Operations

 

Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. Compared to conventional surgery, Gamma Knife radiosurgery usually is an out-patient procedure with lower risk of complications and can be provided at a lower cost. Typically, Gamma Knife patients resume their pre-surgical activities one or two days after treatment. The Gamma Knife Perfexion unit, which was introduced by Elekta in 2006, treats patients with 192 single doses of gamma rays that are focused with great precision on small and medium sized, well circumscribed and critically located structures in the brain. The Cobalt-60 sources coverage at the target area and deliver a dose that is high enough to destroy the diseased tissue without damaging the surrounding healthy tissue. In 2015, Elekta introduced an upgrade to the Gamma Knife Perfexion unit called Icon. As of March 1, 2019, all of the Company’s sixteen (16) Gamma Knife units in the United States were Gamma Knife Perfexion units.

 

The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). Research is being conducted to determine whether the Gamma Knife can be effective in the treatment of epilepsy, tremors, and other functional disorders.

 

As of December 31, 2018, there were approximately 116 Gamma Knife sites in the United States and more than 335 units in operation worldwide. Based on recent data, an estimated percentage breakdown of Gamma Knife procedures performed in the U.S. by indications treated is as follows: malignant (61%) and benign (23%) brain tumors, vascular disorders (4%), and functional disorders (12%).

 

4

 

 

The Company, as of March 1, 2019, had sixteen (16) operating Gamma Knife units located in the United States and one in Lima, Peru. The Company’s first Gamma Knife commenced operation in September 1991. The Company’s Gamma Knife units performed 1,460 procedures in 2018 for a cumulative total of approximately 40,500 procedures from commencement through December 31, 2018.

 

Revenue from Gamma Knife services for the Company during each of the last five (5) years ended December 31, and the percentage of total revenue of the Company represented by the Gamma Knife for each of the last five years, are set forth below:

 

Year Ended

December 31,

 

Total Gamma Knife

Revenue (in thousands)

  

Gamma Knife % of

Total Revenue

 
2018  $13,578    68.9%
2017  $14,848    75.9%
2016  $16,076    86.0%
2015  $16,077    97.2%
2014  $14,521    94.2%

 

The Company conducts its Gamma Knife business through its 81% indirect interest in GKF. The remaining 19% interest is indirectly owned by Elekta. GKF, formed in October 1995, is managed by its policy committee. The policy committee is composed of one representative from the Company, Ernest A. Bates, M.D., ASHS’s Chairman and CEO, and one representative from Elekta. The policy committee sets the operating policy for GKF. The policy committee may act only with the unanimous approval of both of its members. The policy committee selects a manager to handle GKF’s daily operations. Craig K. Tagawa, Chief Executive Officer of GKF and Chief Operating and Financial Officer of ASHS, serves as GKF’s manager.

 

GKF’s profits and/or losses and any cash distributions are allocated based on membership interests. GKF’s operating agreement requires that it have a cash reserve of at least $50,000 before cash distributions are made to its members. From inception to December 31, 2018, GKF has distributed $48,276,000 to the Company and $11,324,000 to the non-controlling member.

 

Image Guided Radiation Therapy Operations (“IGRT”)

 

The Company’s radiation therapy business currently consists of one IGRT system that began operation in September 2007 at an existing Gamma Knife customer site. Revenue generated under IGRT services accounted for approximately 5.5% of the Company’s total revenue in 2018. This contract is currently on a month-to-month basis and the Company expects it will terminate sometime in the second quarter of 2019.

 

IGRT technology integrates imaging and detection components into a state-of-the-art linear accelerator, allowing clinicians to plan treatment, verify positioning, and deliver treatment with a single device, providing faster, more effective radiation therapy with less damage to healthy tissue.  IGRT captures cone beam imaging, fluoroscopic and/or x-ray images on a daily basis, creating three-dimensional images that pinpoint the exact size, location and coordinates of tumors. Once tumors are pinpointed, the system delivers ultra-precise doses of radiation which ultimately leads to improved patient outcomes.

 

Based on the most recently available information, there are approximately 4,000 linear accelerator-based radiation therapy units installed in the United States, and it is estimated that a majority of these units provide Intensity-Modulated Radiation Therapy (“IMRT”), IGRT or a combination of this advanced radiation therapy capability. Radiation therapy services are provided through approximately 2,300 hospital-based and free-standing oncology centers.

 

5

 

 

Additional information on our operations can be found in Item 6– “Selected Financial Data”, Item 7– “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 1 of our consolidated financial statements.

 

Proton Beam Radiation Therapy Operations (“PBRT”)

 

PBRT is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. PBRT, first clinically introduced in the 1950s, has physics advantages compared to photon-based systems which allow PBRT to deliver higher radiation doses to the tumor with less radiation to healthy tissue. PBRT currently treats prostate, brain, spine, head and neck, lung, breast, gastrointestinal tract and pediatric tumors. More than 180,000 patients have been treated with protons worldwide.

 

Introduction of PBRT in the United States, until recently, has been limited due to the high capital costs of these projects. The Company believes that the current development of one and two treatment room PBRT systems at lower capital costs and the level of reimbursement for PBRT from the Centers for Medicare & Medicaid Services (“CMS”) will help make this technology available to a larger segment of the market.

 

CUSTOMERS

 

The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services. The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services. The majority of the Company’s customers pay the Company on a revenue sharing basis. The market for these services primarily consists of large and medium sized medical centers. The business is capital intensive; the total cost of a Gamma Knife or IGRT facility usually ranges from $3.0 million to $5.5 million, including equipment, site construction and installation; the total cost of a single room PBRT system usually ranges from $30.0M to $40.0M, inclusive of equipment, site construction and installation. The Company pays for the equipment and the medical center generally pays for site and installation costs. The following is a listing of the Company’s sites as of March 1, 2019:

 

Customers (Gamma Knife except as noted)   Original Term of
Contract
  Year Contract
Began
  Basis of Payment
             
Southwest Texas Methodist Hospital San Antonio, Texas   10 years   1998   Fee per use
Kettering Medical Center Kettering, Ohio   10 years   1999   Revenue sharing
Tufts Medical Center Boston, Massachusetts   10 years   1999   Fee per use
University of Arkansas for Medical Sciences Little Rock, Arkansas   15 years   1999   Revenue sharing
Central Mississippi Medical Center Jackson, Mississippi   10 years   2001   Fee per use
OSF Saint Francis Medical Center Peoria, Illinois   10 years   2001   Fee per use
Albuquerque Regional Medical Center   10 years   2003   Fee per use
Albuquerque, New Mexico Northern Westchester Hospital   10 years   2005   Fee per use
Mt. Kisco, New York Tufts Medical Center (IGRT)   10 years   2007   Revenue Sharing
Boston, Massachusetts USC University Hospital   10 years   2008   Fee per use
Los Angeles, California Ft. Sanders Regional Medical Center   10 years   2011   Revenue Sharing
Knoxville, Tennessee St. Vincent’s Medical Center   10 years   2011   Revenue Sharing
Jacksonville, Florida Sacred Heart Medical Center   10 years   2013   Revenue Sharing
Pensacola, Florida PeaceHealth Sacred Heart Medical Center at RiverBend Eugene, Oregon   10 years   2014   Revenue Sharing
Orlando Health – UF Health Cancer Center Orlando, Florida (PBRT)   10 years   2016   Revenue Sharing
Bryan Medical Center Lincoln, Nebraska   10 years   2017   Revenue Sharing
Methodist Hospital Merrillville, Indiana   10 years   2019   Revenue Sharing

  

6

 

 

The Company’s typical fee per use agreement is for a ten-year term. The fixed fee per use reimbursement amount that the Company receives from the customer is based on the Company’s cost to provide the service and the anticipated volume of the customer. The Gamma Knife contracts signed by the Company typically call for a fee ranging from $6,000 to $9,300 per procedure. There are no minimum volume guarantees required of the customer. In most cases, GKF is responsible for providing the Gamma Knife and related ongoing Gamma Knife equipment expenses (i.e., personal property taxes, insurance, and equipment maintenance) and helps fund the customer’s Gamma Knife marketing. The customer generally is obligated to pay site and installation costs and the costs of operating the Gamma Knife. The customer can either renew the agreement or terminate the agreement at the end of the contractual term. If the customer chooses to terminate the agreement, then GKF removes the equipment from the medical center for possible placement at another site.

 

The Company’s typical revenue sharing agreements (“retail”) are for a period of ten years. Instead of receiving a fixed fee, the Company receives all or a percentage of the reimbursement (exclusive of physician fees) received by the customer. The Company is at risk for any reimbursement rate changes for radiosurgery or radiation therapy services by the government or other third-party payors. There are no minimum volume guarantees required of the customer.

 

One customer accounted for approximately 26%, 21%, and 10% of the Company’s total revenue in 2018, 2017 and 2016, respectively. At December 31, 2018 and 2017, three customers individually accounted for more than 10% of total accounts receivable, in the respective years.

 

MARKETING

 

The Company markets its Gamma Knife services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development, its Chief Operating Officer and its Chief Executive Officer. The Company markets its PBRT service through a direct sales effort led by its Vice President of Sales and Business Development, its Chief Operating Officer and its Chief Executive Officer. The major advantages to a health care provider in contracting with the Company for its services include:

 

§The medical center avoids the high cost of owning the equipment. By not acquiring the equipment supplied by the Company, the medical center is able to allocate the funds otherwise required to purchase and/or finance the equipment to other projects.

 

§The Company does not have minimum volume requirements, so the medical center avoids the risk of equipment under-utilization. The medical center pays the Company only for each procedure performed on a patient.

 

7

 

 

§For contracts under revenue sharing arrangements, the Company assumes all or a portion of the risk of reimbursement rate changes. The medical center pays the Company only the contracted portion of revenue received from each procedure.

 

§The medical center transfers the risk of technological obsolescence to the Company. The medical center and its physicians are not under any obligation to utilize technologically obsolete equipment.

 

§The Company provides planning, installation, operating and marketing assistance and support to its customers.

 

FINANCING

 

The Company’s Gamma Knife business is operated through GKF. GKF generally finances its U.S. Gamma Knife units, upgrades and additions with loans or capital leases from various finance companies for typically 100% of the cost of each Gamma Knife, plus any sales tax, customs, and duties. The financing is predominantly fully amortized over an 84-month period and is collateralized by the equipment, customer contracts and accounts receivable, and is generally without recourse to the Company and Elekta. The lease financing obtained by Orlando is guaranteed by the Company and collateralized by the equipment, customer contract and accounts receivable related to this project.

 

COMPETITION

 

Conventional neurosurgery, radiation therapy and other radiosurgery devices are the primary competitors of Gamma Knife radiosurgery. Gamma Knife radiosurgery has gained acceptance as an alternative and/or adjunct to conventional surgery due to its more favorable morbidity outcomes for certain procedures as well as its non-invasiveness. Utilization of the Company’s Gamma Knife units is contingent on the acceptance of Gamma Knife radiosurgery by the customer’s neurosurgeons, radiation oncologists and referring physicians. In addition, the utilization of the Company’s Gamma Knife units is impacted by the proximity of competing Gamma Knife centers and providers using other radiosurgery devices.

 

Conventional linear accelerator-based radiation therapy is the primary competitor of the Company’s proton therapy system at Orlando Health. Proton beam radiation therapy although available for many years is only recently emerging as a more clinically beneficial alternative to conventional linear accelerators for certain tumors. Utilization of the Company’s proton therapy system is dependent on the acceptance of this technology by Orlando Health’s radiation oncologists and referring physicians, as well as patient self-referrals. There are currently no competing proton therapy facilities near the Company’s site.

 

There are several competing manufacturers of PBRT systems, including Mevion, IBA Particle Therapy Inc., Varian Medical Systems, Inc., Hitachi Ltd., ProNova Solutions, LLC, Sumitomo Heavy Industries, ProTom International, Inc. and Mitsubishi Electric. The Company has purchased one MEVION S250 and has made deposits towards the purchase of two additional MEVION S250 systems. The Mevion system, as well as single room proton therapy systems from other manufacturers, potentially provides cancer centers the opportunity to introduce single treatment room PBRT services with a cost in the range of approximately $30 to $40 million versus four and five PBRT treatment room programs costing in excess of $120 million. The MEVION S250 system received FDA approval in the second quarter of 2012 and the first clinical treatment occurred in December 2013 at Barnes-Jewish Hospital. The MEVION S250i (Hyperscan) unit, which includes pencil beam scanning, was FDA approved in December 2017. The Company’s first MEVION S250 system in operation at Orlando Health treated its first patient in April 2016. The Company currently does not have customer contracts for its second and third PBRT units.

 

The Company believes the business model it has developed for use in its Gamma Knife and IGRT placements can be tailored for the PBRT market segment. The Company is targeting large, hospital-based cancer programs. The Company’s ability to develop a successful PBRT financing entity depends on the decision of cancer centers to self-fund or to fund the PBRT through conventional financing vehicles, the Company’s ability to capture market share from competing alternative PBRT financing entities, and the Company’s ability to raise capital to fund PBRT projects.

 

8

 

 

The Company’s ability to secure additional customers for Gamma Knife services and other proton beam radiation therapy services, or other equipment, is dependent on its ability to effectively compete against the manufacturers of these systems selling directly to potential customers and other companies that outsource these services. The Company does not have an exclusive relationship with any manufacturer and has previously lost sales to customers that chose to purchase equipment directly from manufacturers. The Company may continue to lose future sales to such customers and may also lose sales to the Company’s competitors.

 

GOVERNMENT PROGRAMS

 

The Medicare program is administered by CMS of the U.S. Department of Health and Human Services. Medicare is a health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets.

 

The Medicare program is subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions, all of which could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to patients and the timing of payments to our client hospitals.

 

The Company’s Gamma Knife, PBRT and IGRT customers receive payments for patient care from federal government and private insurer reimbursement programs. Currently in the United States, Gamma Knife, proton therapy and IGRT services are performed primarily on an out-patient basis. Gamma Knife patients with Medicare as their primary insurer, treated on either an in-patient or out-patient basis, comprise an estimated 35%-45% of the total Gamma Knife patients treated nationwide. PBRT and IGRT patients with Medicare as their primary insurer are treated primarily on an out-patient basis and comprise an estimated 45% to 50% of the total radiation therapy patients treated.

 

Congress enacted legislation in 2013 that significantly reduced the Medicare reimbursement rate for outpatient Gamma Knife treatment by setting it at the same amount paid for linear accelerator-based radio surgery treatment. Prior to April 1, 2013, Medicare’s reimbursement rate for Gamma Knife treatment had been relatively stable. The Company’s IGRT services are reimbursed by CMS and other insurers. Reimbursement for these services has remained fairly stable. See additional discussion under “Item 1A Risk Factors”.

 

The average Medicare reimbursement rate trends from 2015 to 2019 are outlined below:

 

Average Medicare Reimbursement Rate Trends - Gamma Knife

 

 2015    2016    2017    2018    2019 
$9,700   $8,800   $9,000   $9,100   $9,300 

 

The average Medicare reimbursement rate trends for PBRT from 2016 to 2019 are outlined below. Patients typically undergo 25-40 delivery sessions.

 

Average Medicare Reimbursement Rate Trends - PBRT

 

   2016   2017   2018   2019 
Simple without Compensation  $506   $494   $522   $520 
Simple with Compensation, Intermediate, or Complex  $1,051   $994   $1,053   $1,079 

 

We are unable to predict the effect of future government health care funding policy changes on operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if one or more of our hospital clients are excluded from participation in the Medicare program or any other government health care program, there could be a material adverse effect on our business.

 

9

 

  

Affordable Care Act and Subsequent Regulation

 

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, (“Affordable Care Act”), which has resulted in significant changes to the health care industry. The primary goal of the legislation was to extend health care coverage to uninsured legal U.S. residents through both an expansion of public programs and reforms to private sector health insurance. The expansion of insurance coverage was expected to be funded in part by measures designed to promote quality and cost efficiency in health care delivery and by budgetary savings in the Medicare and Medicaid programs. Because the Company is not a health care provider, we were not directly affected by the law, but we could be indirectly affected principally as follows:

 

·An increase in the number of insured residents could potentially increase the number of patients seeking Gamma Knife or radiation therapy treatment.

 

·The Company’s retail contracts are subject to reimbursement rate changes for radiosurgery or radiation therapy services by the government or other third-party payors. Any changes to Medicare or Medicaid reimbursement through the repeal or modification of the Affordable Care Act could affect revenue generated from these sites.

 

Some of the provisions of the Affordable Care Act have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges as well as recent efforts by the current U.S. President’s administration to repeal or replace certain aspects of the Affordable Care Act. Since January 2017, the current U.S. President has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the Affordable Care Act such as removing penalties, starting January 1, 2019, for not complying with the Affordable Care Act’s individual mandate to carry health insurance and delaying the implementation of certain Affordable Care Act-mandated fees. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the Affordable Care Act are invalid as well. While the Texas District Court Judge, as well as the current U.S. President’s administration and CMS, have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act.

 

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the then-U.S. President signed into law the American Taxpayer Relief Act of 2012, which, among other things, also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. It is unclear what effect, if any, the shifting legislative and other governmental proposals would have on our business.

  

GOVERNMENT REGULATION

 

The payment of remuneration to induce the referral of health care business has been a subject of increasing governmental and regulatory focus in recent years. Section 1128B(b) of the Social Security Act (sometimes referred to as the "federal anti-kickback statute") provides criminal penalties for individuals or entities that offer, pay, solicit or receive remuneration in order to induce referrals for items or services for which payment may be made under the Medicare and Medicaid programs and certain other government funded programs. The Affordable Care Act amended the anti-kickback statute to eliminate the requirement of actual knowledge, or specific intent to commit a violation, of the anti-kickback statute. The Social Security Act provides authorizes the Office of Inspector General through civil proceedings to exclude an individual or entity from participation in the Medicare and state health programs if it is determined any such party has violated Section 1128B(b) of the Social Security Act. However, the federal anti-kickback statute is subject to evolving interpretations. In the past, the government has enforced the federal anti-kickback statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The Company believes that it is in compliance with the federal anti-kickback statute. Additionally, the majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.

 

Additionally, the Omnibus Budget Reconciliation Act of 1993, often referred to as "Stark II", bans physician self-referrals to providers of designated health services with which the physician has a financial relationship. On September 5, 2007, the third and final phase of the Stark regulations (Phase III) was published. The term "designated health services" includes, among others, radiation therapy services and in-patient and out-patient hospital services. On January 1, 1995, the Physician Ownership and Referral Act of 1993 became effective in California. This legislation prohibits physician self-referrals for covered goods and services, including radiation oncology, if the physician (or the physician's immediate family) concurrently has a financial interest in the entity receiving the referral. The Company believes that it is in compliance with these rules and regulations.

 

On August 19, 2008, the CMS published a final rule relating to inpatient hospital services paid under the Inpatient Prospective Payment System for discharges in the Fiscal Year 2009 (the “Final Rule”). Among other things, the Final Rule prohibits “per-click payments” to certain physician lessors for services rendered to patients who were referred by the physician lessor. This prohibition on per-click payments for leased equipment used in the treatment of a patient referred to a hospital lessee by a physician lessor applies regardless of whether the physician himself or herself is the lessor or whether the lessor is an entity in which the referring physician has an ownership or investment interest. The effective date of this prohibition was October 1, 2009. However, referrals made by a radiation oncologist for radiation therapy or ancillary services necessary for, and integral to, the provision of radiation therapy (such as Gamma Knife services) are not subject to this prohibition so long as certain conditions are met. GK Financing’s majority owned subsidiaries, AGKE and JGKE have minority ownership interests that are held solely by radiation oncologists, who are otherwise exempt from the referral prohibition under the Final Rule. The Company believes it is in compliance with the Final Rule.

 

10

 

 

A range of federal civil and criminal laws target false claims and fraudulent billing activities. One of the most significant is the Federal False Claims Act, which prohibits the submission of a false claim or the making of a false record or statement in order to secure a reimbursement from a government-sponsored program. In recent years, the federal government has launched several initiatives aimed at uncovering practices which violate false claims or fraudulent billing laws. Claims under these laws may be brought either by the government or by private individuals on behalf of the government, through a "whistleblower" or "qui tam" action. The Company believes that it is in compliance with the Federal False Claims Act; however, because such actions are filed under seal and may remain secret for years, there can be no assurance that the Company or one of its affiliates is not named in a material qui tam action.

 

Legislation in various jurisdictions requires that health facilities obtain a Certificate of Need ("CON") prior to making expenditures for medical technology in excess of specified amounts. Four of the Company’s existing customers were required to obtain a CON or its equivalent. The CON procedure can be expensive and time consuming and may impact the length of time before Gamma Knife services commence. CON requirements vary from state to state in their application to the operations of both the Company and its customers. In some jurisdictions the Company is required to comply with CON procedures to provide its services and in other jurisdictions customers must comply with CON procedures before using the Company's services. The Company is unable to predict if any jurisdiction will eliminate or alter its CON requirements in a manner that will increase competition and, thereby, affect the Company's competitive position.

 

The Company's Gamma Knife units contain Cobalt 60 radioactive sources. The medical centers that house the Company's Gamma Knife units are responsible for obtaining possession and user's licenses for the Cobalt 60 source from the Nuclear Regulatory Commission. The Company’s Gamma Knife center in Peru was responsible for obtaining possession and user’s licenses for the Cobalt-60 sources from the Peruvian Regulatory Agencies.

 

Standard linear accelerator equipment utilized to treat patients is regulated by the FDA. The licensing is obtained by the individual medical center operating the equipment.

 

The Company believes it is in substantial compliance with the various rules and regulations that affect its businesses.

 

INSURANCE AND INDEMNIFICATION

 

The Company's contracts with equipment vendors generally do not contain indemnification provisions. The Company maintains a comprehensive insurance program covering the value of its property and equipment, subject to deductibles, which the Company believes are reasonable.

 

The Company's customer contracts generally contain mutual indemnification provisions. The Company maintains general and professional liability insurance in the United States. The Company is not involved in the practice of medicine and therefore believes its present insurance coverage and indemnification agreements are adequate for its business. The Company’s Peruvian Gamma Knife center is a free-standing facility operated by GKPeru. GKPeru’s treating physicians and clinical staff are independent contractors. The Company maintains general and professional liability insurance consistent with the operations of this facility and believes its present coverage is adequate for its business.

 

EMPLOYEES

 

At December 31, 2018, the Company employed nine (9) people on a full-time basis in the United States and three (3) people on a full-time basis in Lima, Peru. None of these employees is subject to a collective bargaining agreement and there is no union representation within the Company. The Company maintains various employee benefit plans and believes that its employee relations are good.

 

11

 

 

EXECUTIVE OFFICERS OF THE COMPANY

 

The following table provides current information concerning those persons who serve as executive officers of the Company. The executive officers were appointed by the Board of Directors and serve at the discretion of the Board of Directors.

 

Name:   Age:   Position:
Ernest A. Bates, M.D.   82   Chairman of the Board of Directors and Chief Executive Officer
Craig K. Tagawa   65   Senior Vice President - Chief Operating and Financial Officer
Ernest R. Bates   52   Vice President of Sales and Business Development

 

Ernest A. Bates, M.D., founder of the Company, has served in the positions listed above since the incorporation of the Company. A board-certified neurosurgeon, Dr. Bates is Emeritus Vice Chairman of the Board of Trustees at Johns Hopkins University and serves on the Johns Hopkins Neurosurgery Advisory Board. He also serves on the boards of Shared Imaging and The School of Nursing Dean’s Advisory Council at UCSF. Dr. Bates currently serves as President and Director of the Ernest Bates Foundation. From 1981-1987 he was a member of the Board of Governors of the California Community Colleges, and he served on the California High Speed Rail Authority from 1997 to 2003. Dr. Bates is a member of the Board of Overseers at the University of California, San Francisco, School of Nursing. He is a graduate of the School of Arts and Sciences of the Johns Hopkins University, and he earned his medical degree at the University of Rochester School of Medicine and Dentistry.

 

Craig K. Tagawa has served as Chief Operating Officer since February 1999 in addition to serving as Chief Financial Officer since May 1996. Mr. Tagawa also served as Chief Financial Officer from January 1992 through October 1995. Previously a Vice President in such capacity, Mr. Tagawa became a Senior Vice President on February 28, 1993. He is also the Chief Executive Officer of GKF. From September 1988 through January 1992, Mr. Tagawa served in various positions with the Company. Mr. Tagawa currently serves as Chief Financial Officer and Secretary of the Ernest Bates Foundation. He is a former Chair of the Industrial Policy Advisory Committee of the Engineering Research Center for Computer-Integrated Surgical Systems and Technology at The Johns Hopkins University. He received his undergraduate degree from the University of California at Berkeley and his M.B.A. from Cornell University.

 

Ernest R. Bates joined the Company in January 2007 as Vice President of Sales and Business Development. He was on the Board of Directors of the Company from 2004 through February 2007. Prior to joining the Company, he had been Managing Director, Institutional Fixed Income Sales of HSBC Securities (USA), Inc. since 2003. Mr. Bates has also served as Managing Director, Head of Asian Product for HSBC Securities (USA) Inc. from 1999 to 2003. From 1993 through 1999, Mr. Bates held various positions with Merrill Lynch, last serving as Vice President, European Syndicate for Merrill Lynch International. He received his undergraduate degree from Brown University and a M.B.A. degree from The Wharton Business School. Ernest R. Bates is the son of Chairman of the Board and Chief Executive Officer Dr. Ernest A. Bates.

 

AVAILABLE INFORMATION

 

Our Internet address is www.ashs.com. We make available free of charge, through our Internet website under the “Investor Center” tab in the “Corporate” section, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (“Exchange Act”) as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The information contained on our Internet website is not part of this document.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information in this report, the following factors could affect our future business, results of operations, cash flows or financial position, and could cause future results to differ materially from those expressed in any of the forward-looking statements contained in this report.

 

12

 

 

The Federal Reimbursement Rate for Gamma Knife Treatments Has Fluctuated

Congress enacted legislation in 2013 that significantly reduced the Medicare reimbursement rate for outpatient Gamma Knife treatment by setting it at the same amount paid for linear accelerator-based radiosurgery treatment. Prior to April 1, 2013, Medicare’s reimbursement rate for Gamma Knife treatment had been relatively stable. There can be no assurance that CMS reimbursement levels will be maintained at levels providing the Company an adequate return on its investment. Any future reductions in the reimbursement rate would adversely affect the Company’s revenues and financial results.

 

The average Medicare reimbursement rate trends from 2015 to 2019 are outlined below:

 

Average Medicare Reimbursement Rate Trends

 

 2015    2016    2017    2018    2019 
$9,700   $8,800   $9,000   $9,100   $9,300 

 

The Company’s Capital Investment at Each Site is Substantial

 

Each Gamma Knife, PBRT or IGRT device requires a substantial capital investment. In some cases, we contribute additional funds for capital costs and/or annual operating and equipment related costs such as marketing, maintenance, insurance and property taxes. Due to the structure of our contracts with medical centers, there can be no assurance that these costs will be fully recovered or that we will earn a satisfactory return on our investment.

 

The Market for the Gamma Knife is Limited

 

There is a limited market for the Gamma Knife, and the market in the United States may be mature. The Company has begun operation at only six (6) new Gamma Knife sites in the United States since 2011. Due to the substantial costs of acquiring a Gamma Knife unit, we must identify medical centers that possess neurosurgery and radiation oncology departments capable of performing a large number of Gamma Knife procedures. As of December 31, 2018, there were approximately 116 operating Gamma Knife units in the United States, of which fifteen (15) units were owned by the Company. As of December 31, 2018, the Company has one idle Gamma Knife unit with a cumulative net book value of $729,000. There are currently no commitments to place into service or trade this unit in during 2019. There can be no assurance that we will be successful in placing these idle units or additional units at any sites in the future. The Company’s existing contracts with its customers are fixed in length and there can be no assurance that the customers will wish to extend the contract beyond the end of the term.

 

The Company Has a High Level of Debt and May Incur Additional Debt to Finance its Operations

 

The Company’s business is capital intensive. The Company finances its Gamma Knife units through its GKF subsidiary. The amounts financed through GKF have been generally non-recourse to ASHS. The Company financed its first proton therapy unit through its wholly-owned subsidiary, Orlando, and guaranteed the lease financing. The Company’s combined long-term debt and capital leases totaled $20,166,000 as of December 31, 2018 and is collateralized by its Gamma Knife, MEVION S250 and other assets, including accounts receivable and future proceeds from any contract between the Company and any end user of the financed equipment. Depending on the Company’s financing requirements and market conditions, the Company may seek to finance its operations by incurring additional long-term debt in the future. The Company’s current level of debt may adversely affect the Company’s ability to secure additional credit in the future, and as a result may affect operations and profitability. If a default on debt occurs in the future, the Company’s creditors would have the ability to accelerate the defaulted loan, to seize the Gamma Knife or MEVION S250 units or other equipment with respect to which default has occurred, and to apply any collateral they may have at the time to cure the default.

 

A Small Number of Customers Account for a Major Portion of our Revenues

 

A limited number of customers have historically accounted for a substantial portion of the Company’s total revenue, and the Company expects such customer concentration to continue for the foreseeable future. For example, in 2018, four (4) customers in total accounted for approximately 50% of the Company’s revenue. The loss of a significant customer or a significant decline in the business from the Company’s largest customers could have a material adverse effect on the Company’s business and results of operations.

 

13

 

 

The Market for the Company’s Services is Competitive

 

The Company estimates that there are two other companies that actively provide alternative, non-conventional Gamma Knife financing to potential customers. We believe there are no competitor companies that currently have more than three (3) Gamma Knife units in operation. The Company’s relationship with Elekta, the manufacturer of the Leksell Gamma Knife unit, is non-exclusive, and in the past the Company has lost sales to customers that chose to purchase a Gamma Knife unit directly from Elekta. The Company also has several competitors in the financing of proton therapy projects. The Company’s business model differs from its competitors, but there can be no assurances that the Company will not lose placements to its competitors. In addition, the Company may continue to lose future sales to customers purchasing equipment directly from manufacturers. There can be no assurance that the Company will be able to successfully compete against others in placing future units.

 

There are Alternatives to the Gamma Knife

 

Other radiosurgery devices and conventional neurosurgery compete against the Gamma Knife. Each of the medical centers targeted by the Company could decide to acquire another radiosurgery device instead of a Gamma Knife. In addition, neurosurgeons who are responsible for referring patients for Gamma Knife surgery may not be willing to make such referrals for various reasons, instead opting for invasive surgery. There can be no assurance that the Company will be able to secure a sufficient number of future sites or Gamma Knife procedures to sustain its profitability and growth.

 

International Operations

 

The Company installed a Gamma Knife in Lima, Peru in 2017. International operations can be subject to exchange rate volatility which could have an adverse effect on our financial results and cash flows. In addition, international operations can be subject to legal and regulatory uncertainty and political and economic instability, which could result in problems asserting property or contractual rights, potential tariffs, increased compliance costs, increased regulatory scrutiny, potential adverse tax consequences, the inability to repatriate funds to the United States, and the Company’s inability to operate in those locations.

 

New Technology and Products Could Result in Equipment Obsolescence

 

There is constant change and innovation in the market for highly sophisticated medical equipment. New and improved medical equipment can be introduced that could make the Gamma Knife technology obsolete and that would make it uneconomical to operate. During 2000, Elekta introduced an upgraded Gamma Knife which cost approximately $3.6 million plus applicable tax and duties. This upgrade includes an Automatic Positioning System™ (“APS”), and therefore involved less health care provider intervention. In early 2005, Elekta introduced a new upgrade, the Gamma Knife Model 4C (“Model 4C”). The cost to upgrade existing units to the Model 4C with APS was approximately $200,000 to $1,000,000, depending on the current Gamma Knife configuration. In 2006 Elekta introduced a new model of the Gamma Knife, the Perfexion, which costs approximately $4.5 million plus applicable taxes and duties. The Perfexion can perform procedures faster than previous Gamma Knife models and it involves less health care personnel intervention. In 2015, Elekta introduced the Leksell Gamma Knife Icon TM. The Perfexion is upgradeable to the Icon platforms which has enhanced imaging capabilities allowing for treatment without a head frame and the treatment of larger tumors. Existing model 4Cs of the Gamma Knife are not upgradeable to the Perfexion model. As of March 1, 2019, all the Company’s Gamma Knife units in the United States are Perfexion models. The failure to acquire or use new technology and products could have a material adverse effect on our business and results of operations.

 

The Company Has Invested in a Proton Beam Business

 

We have committed a substantial amount of our financial resources to next-generation proton beam technology. The first MEVION S250 system began treating patients in December 2013. The Company’s first MEVION S250 system began treating patients in April 2016. The Company has committed to purchase two (2) additional MEVION S250 systems and has already made deposits of $2,250,000 towards this commitment. There can be no assurance that we will be able to finance the two additional systems.

 

The Trading Volume of Our Common Stock is Low

 

Although our common stock is listed on the NYSE American, our common stock has historically experienced low trading volume. Reported average daily trading volume in our common stock for the three-month period ended December 31, 2018 was approximately 16,000 shares. There is no reason to think that a more significant active trading market in our common stock will develop in the future. Limited trading volume subjects our common stock to greater price volatility and may make it difficult for you to sell your shares in a quantity or at a price that is attractive to you.

 

14

 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2. PROPERTIES

 

The Company's corporate offices are located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leases approximately 3,253 square feet for $19,556 per month with a lease expiration date in August 2023. Prior to the Company’s relocation in 2016, it leased approximately 4,640 square feet for $25,128 per month and subleased approximately 3,500 square feet of the office space for $16,042 per month. The sublease expired in May 2016. The Company also has a satellite office in Fairfield, California, where it leases 895 square feet for $2,865 per month with a lease expiration date in April 2020.

 

For the year ended December 31, 2018 the Company's aggregate net rental expenses for all properties were approximately $298,000.

 

ITEM 3. LEGAL PROCEEDINGS

 

There are no material pending legal proceedings involving the Company or any of its property. The Company knows of no legal or administrative proceedings against the Company contemplated by governmental authorities.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information and Dividend Policy

 

The Company's common shares, no par value (the "Common Shares"), are currently traded on the New York Stock Exchange. At December 31, 2018, the Company had 5,714,000 issued and outstanding common shares, 613,000 common shares reserved for options, 4,000 unvested restricted stock units issued, 272,000 vested restricted stock units and 129,000 restricted stock awards reserved for issuance.

 

The following table sets forth the high and low closing sale prices of the Common Shares of the Company on the New York Stock Exchange for each full quarter for the last two fiscal years.

 

   Prices for Common Shares 
Quarter Ending  High   Low 
March 31, 2017  $4.53   $3.35 
June 30, 2017  $4.75   $3.80 
September 30, 2017  $4.05   $2.80 
December 31, 2017  $3.15   $2.50 
March 31, 2018  $2.87   $2.50 
June 30, 2018  $2.89   $2.30 
September 30, 2018  $3.50   $2.65 
December 31, 2018  $3.89   $2.33 

 

15

 

 

The Company estimates that there were approximately 1,100 beneficial holders of its Common Shares at December 31, 2018.

 

There were no dividends declared or paid during 2018, 2017, or 2016.

 

Stock Repurchase Program

In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its common stock on the open market from time to time at prevailing prices, and in 2008 the Board of Directors reaffirmed these authorizations. In 2018, 2017, and 2016 there were no shares repurchased by the Company. A total of approximately 928,000 shares have been repurchased in the open market pursuant to these authorizations at a cost of approximately $1,957,000. As of December 31, 2018, there were approximately 72,000 shares remaining under the repurchase authorizations.

 

Shareholder Rights Plan

On March 22, 1999, the Company adopted a Shareholder Rights Plan (“Plan”). Under the Plan, the Company made a dividend distribution of one Right for each outstanding share of the Company’s common stock as of the close of business on April 1, 1999. The Rights become exercisable only if any person or group, with certain exceptions, becomes an “acquiring person” (acquires 15% or more of the Company’s outstanding common stock) or announces a tender or exchange offer to acquire 15% or more of the Company’s outstanding common stock. The Company’s Board of Directors adopted the Plan to protect shareholders against a coercive or inadequate takeover offer. On March 12, 2009, the Board of Directors approved the First Amendment to the Plan which, among other things, extended the final date on which the Rights are exercisable until the close of business on April 1, 2019.

 

Equity Compensation Plans

During 2018, 4,000 restricted stock units, 31,000 restricted stock units for deferred compensation and 16,000 options were issued. Additional information regarding our equity compensation plans is incorporated herein by reference from the 2019 Proxy Statement. Also, see Note 8 - “Shareholders’ Equity to the Consolidated Financial Statements”.

 

16

 

 

ITEM 6. SELECTED FINANCIAL DATA

 

Summary of Operations

 

   Year Ended December 31, 
   (Amounts in thousands except per share data) 
   2018   2017   2016   2015   2014 
Revenue  $19,714   $19,556   $18,700   $16,548   $15,417 
Costs of revenue   12,228    10,893    9,905    9,833    10,138 
Selling and administrative expense   3,994    4,323    3,802    3,496    3,630 
Interest expense   1,631    1,927    1,707    1,239    1,699 
Total expenses   17,853    17,143    15,414    14,568    15,467 
Income (loss) from operations   1,861    2,413    3,286    1,980    (50)
Proceeds received from investment in equity securities   22    0    0    0    0 
(Loss) on write-down investment in equity securities   0    (579)   0    (2,140)   0 
(Loss) on early extinguishment of debt   0    0    (108)   0    0 
(Loss) on sale of subsidiary   0    0    0    0    (572)
Gain foreign currency transactions   0    0    0    0    161 
Interest and other income   198    3    15    18    28 
Income (loss) before income taxes   2,081    1,837    3,193    (142)   (433)
Income tax expense (benefit)   451    (1,103)   943    434    129 
Net income (loss)   1,630    2,940    2,250    (576)   (562)
Less net income attributable to non-controlling interest   (607)   (1,017)   (1,320)   (946)   (390)
Net income (loss) attributable to ASHS  $1,023   $1,923   $930   $(1,522)  $(952)
Net income (loss) per common share attributable to ASHS:                         
Basic  $0.18   $0.33   $0.17   $(0.28)  $(0.19)
Diluted  $0.17   $0.33   $0.17   $(0.28)  $(0.19)
See accompanying note (1)                         

 

Balance Sheet Data

 

   As of December 31, 
   (Amounts in thousands) 
   2018   2017   2016   2015   2014 
Cash and cash equivalents  $1,442   $2,152   $2,871   $2,209   $1,059 
Certificate of deposit and securities   0    0    0    0    9,000 
Restricted cash   350    350    250    50    50 
Working capital (deficit)   472    (114)   (815)   (2,691)   (2,004)
Total assets   57,502    58,176    60,598    54,114    67,528 
Advances on line of credit   0    0    0    0    8,780 
Current portion of long-term debt and capital leases   6,526    7,273    7,078    7,005    6,108 
Long-term debt/capital leases, less current portion   13,640    15,870    19,958    16,113    20,776 
Shareholders' equity  $31,048   $29,885   $27,137   $25,180   $26,154 
See accompanying note (1)                         

 

17

 

 

(1) In 1995, the Company entered into an operating agreement granting to American Shared Radiosurgery Services (a California corporation and a wholly-owned subsidiary of the Company) an 81% ownership interest in GKF. During 2010 and 2011, GKF established new operating subsidiaries, EWRS, EWRS Turkey, GKPeru, AGKE, and JGKE, and other subsidiaries that are not yet operational. On June 10, 2014, the Company sold EWRS Turkey. Accordingly, the financial data for the Company presented above include the results of GKF and its subsidiaries for the periods 2014 through 2018.

 

This financial data as of December 31, 2018 and 2017 and for the years ended December 31, 2018 and 2017 should be read in conjunction with our consolidated financial statements and the notes thereto beginning on page A-1 of this report and with Item 7– “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

APPLICATION OF CRITICAL ACCOUNTING POLICIES

 

The Company’s consolidated financial statements are prepared in accordance with generally accepted accounting principles and follow general practices within the industry in which it operates. Application of these principles requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. These estimates, assumptions and judgments are based on information available as of the date of the financial statements; accordingly, as this information changes, the financial statements could reflect different estimates, assumptions and judgments. Certain policies inherently have a greater reliance on the use of estimates, assumptions and judgments and as such have a greater possibility of producing results that could be materially different than originally reported.

 

The most significant accounting policies followed by the Company are presented in Note 2 to the consolidated financial statements. These policies along with the disclosures presented in the other financial statement notes and, in this discussion, and analysis, provide information on how significant assets and liabilities are valued in the financial statements and how those values are determined. Based on the valuation techniques used and the sensitivity of financial statement amounts, and the methods, assumptions and estimates underlying those amounts, management has identified revenue recognition and costs of sales for turn-key and revenue sharing arrangements, and the carrying value of fixed assets and useful lives, and as such could be most subject to revision as new information becomes available. The following are our critical accounting policies in which management’s estimates, assumptions and judgments most directly and materially affect the financial statements:

 

Revenue Recognition - The Company recognizes revenues under Accounting Standards Codification (“ASC”) 840, Leases (“ASC 840”) and ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company has one revenue-generating activity, which consists of equipment leasing to hospitals, and includes the operation of Gamma Knife units by GKF, the operation of one proton therapy unit by Orlando, and the operation of one IGRT site by ASHS.

 

Rental income from medical services – The Company recognizes revenues under ASC 840 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. During 2018, the Company had nine (9) fee per use arrangements and nine (9) retail service arrangements. Under both types of agreements, the hospital is responsible for billing patients and collecting technical component fees for services performed. Revenue associated with installation of the Gamma Knife, PBRT, and IGRT units, if any, is a part of the negotiated lease amount and not a distinctly identifiable amount. The costs, if any, associated with installation of the units are amortized over the period of the related lease to match revenue recognition of these costs.

 

For fee per use agreements, revenue is not estimated because these contracts provide for a fixed fee per procedure and are typically for a ten-year term. Revenue is recognized at the time the procedures are performed, based on each hospital’s contracted rate. There is no guaranteed minimum payment. Costs related to operating the units are charged to costs of operations as incurred, which approximates the recognition of the related revenue. Revenue under fee per use agreements is recorded in accordance with the contract terms.

 

18

 

 

During 2018, ASHS had one (1) agreement, Orlando had one (1) agreement, and GKF had seven (7) agreements that are retail service arrangements. These can be further classified as either “turn-key” arrangements or “revenue sharing” arrangements. For GKF’s seven (7) turn-key sites, GKF is solely responsible for the costs to acquire and install the Gamma Knife. In return, GKF receives payment from the hospital in the amount of its reimbursement from third party payors. Revenue is recognized by the Company during the period in which the procedure is performed and is estimated based on what can be reasonably expected to be paid by the third-party payor to the hospital. The estimate is primarily determined from historical experience and hospital contracts with third party payors. These estimates are reviewed on a regular basis and adjusted as necessary to more accurately reflect the expected payment amount. The Company also records an estimate of operating costs associated with each procedure during the period in which the procedure is performed. For two of the turn-key sites, the Company also shares a percentage of net operating profit. The Company records an estimate of net operating profit based on estimated revenues, less estimated operating costs. Costs are determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company’s estimated operating costs are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. Revenue for turn-key sites is recorded on a gross basis, and the operating expenses the Company reimburses to the hospital are recorded in other operating costs.

 

Under revenue sharing arrangements the hospital shares in the responsibility and risk with the Company for the capital investment to acquire and install the equipment. Unlike our turn-key arrangement, the lease payment under a revenue sharing arrangement is a percentage of reimbursed revenue. Payments are made by the hospital, generally on a monthly basis, to the Company based on an agreed upon percentage allocation of cash collected. Revenue is recognized during the period in which procedures are performed and is estimated based on the reimbursement amount that the Company expects to receive from the hospital for those procedures. This estimate is reviewed on a regular basis and adjusted as necessary to more accurately reflect the expected payment amount. For the year ended December 31, 2018, the Company recognized revenues of approximately $18,987,000 under ASC 840.

 

Revenue from retail arrangements amounted to approximately 70%, 64% and 57% of total revenue for the years ended December 31, 2018, 2017 and 2016, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.

 

Patient income – The Company has a stand-alone facility in Lima, Peru, where a contract exists between GKPeru and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. The Company adopted ASC 606 as of January 1, 2018 using the modified retrospective method. The cumulative effect of adopting ASC 606 did not have a material impact on retained earnings, as reported by the Company, and there was no change to the Company’s IT environment following adoption. Accounts receivable earned by GKPeru were not significant for the year ended December 31, 2018. For the year ended December 31, 2018, the Company recognized revenues of approximately $727,000 under ASC 606.

 

2018 Results

 

For the year ended December 31, 2018, 69% of the Company’s revenue was derived from its Gamma Knife business, 26% was derived from the PBRT system, and the remaining 5% from its IGRT business. For the year ended December 31, 2017, 76% of the Company’s revenue was derived from its Gamma Knife business, 21% was derived from the PBRT system, and the remaining 3% from its IGRT business. For the year ended December 31, 2016, 86% of the Company’s revenue was derived from its Gamma Knife business, 12% was derived from the PBRT system, and the remaining 2% from its IGRT business.

 

TOTAL REVENUE

 

(in thousands)  2018   Increase
(Decrease)
   2017   Increase
(Decrease)
   2016 
Total revenue  $19,714    0.8%  $19,556    4.6%  $18,700 

 

Total revenue in 2018 was generally consistent with 2017. Total revenue in 2017 increased 4.6% compared to 2016 due to the Company’s PBRT unit which became operational in April 2016.

 

Gamma Knife Revenue

 

   2018   Increase
(Decrease)
   2017   Increase
(Decrease)
   2016 
Medical services revenue from Gamma Knife (in thousands)  $13,578    (8.6)%  $14,848    (7.6)%  $16,076 
Number of Gamma Knife procedures   1,460    (10.5)%   1,631    (15.1)%   1,922 
Average revenue per procedure  $9,300    2.2%  $9,104    8.8%  $8,364 

 

19

 

 

Gamma Knife revenue for 2018 was $13,578,000 compared to $14,848,000 in 2017. Gamma Knife revenue for 2018 decreased $1,270,000 compared to 2017 due to three customer contracts that expired in April 2017, August 2017 and April 2018, respectively. Gamma Knife revenue for 2017 was $14,848,000 compared to $16,076,000 in 2016. Gamma Knife revenue for 2017 decreased $1,228,000 compared to 2016, due to two customer contracts that expired in April and August 2017, respectively.

 

The number of Gamma Knife procedures performed in 2018 decreased 171 compared to 2017, due to three customer contracts that expired in April 2017, August 2017, and April 2018, respectively. The number of Gamma Knife procedures performed in 2017 decreased 291 compared to 2016, due to two customer contracts that expired in April and August 2017, respectively.

 

Revenue per procedure increased by $196 and $740 in 2018 and 2017 compared to 2017 and 2016, respectively. For 2018 and 2017, the increase was primarily due to the expiration of a high volume, low reimbursement rate customer contract in April 2017.

 

Proton Therapy Revenue

 

  

 

 

2018 

  

 

Increase

(Decrease) 

  

 

 

2017 

  

 

Increase

(Decrease) 

  

 

 

2016 

 
Medical services revenue from PBRT (in thousands)  $5,042    22.4%  $4,120    91.7%  $2,149 
Number of PBRT fractions   5,141    12.9%   4,554    95.5%   2,330 
Average revenue per fraction  $981    8.4%  $905    (1.8%)  $922 

  

PBRT revenue for 2018 was $5,042,000 compared to $4,120,000 and $2,149,000 in 2017 and 2016, respectively. The number of PBRT fractions performed in 2018 was 5,141 compared to 4,554 and 2,330 in 2017 and 2016. Revenue per fraction in 2018 was $981 compared to $905 and $922 in 2017 and 2016, respectively. The Company’s first MEVION S250 system was place at Orlando Health and treated its first patient in April 2016 and revenues and volumes have continued to increase since its first year of operations.

 

IGRT Revenue

 

(in thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
Medical services revenue from IGRT  $1,094    86.1%  $588    23.8%  $475 

 

IGRT revenue for 2018 was $1,094,000 compared to $588,000 and $475,000 in 2017 and 2016, respectively. IGRT revenue increased for 2018 due to increased volumes at the Company’s existing site.

 

COSTS OF REVENUE

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
Total costs of revenue  $12,228    12.3%  $10,893    10.0%  $9,905 
Percentage of total revenue   62.0%        55.7%        53.0%

 

The Company's costs of revenue, consisting of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites) increased by $1,335,000 in 2018 and $988,000 in 2017 compared to 2017 and 2016, respectively.

 

20

 

 

Maintenance and supplies costs as a percentage of total revenue were 12.2%, 6.9%, and 4.7% in 2018, 2017, and 2016, respectively. Maintenance and supplies costs increased by $1,040,000 and $485,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The increase in 2018 and 2017 compared to 2017 and 2016, respectively, was due to the Company’s PBRT maintenance contract which began September 2017. The PBRT maintenance contract renews annually every September and is for a five (5) year period.

 

Depreciation and amortization costs as a percentage of total revenue were 34.2%, 33.8%, and 33.5% in 2018, 2017 and 2016, respectively. Depreciation and amortization costs increased $144,000 and $339,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The increase in 2018 compared to 2017 was due to depreciation incurred on the Company’s Gamma Knife in Peru, which began operations in July 2017, and depreciation incurred on the PBRT system. The increase in 2017 compared to 2016 was due to depreciation incurred on the PBRT system, which began operations in April 2016.

 

Other direct operating costs as a percentage of total revenue were 15.6%, 15.0%, and 14.8% in 2018, 2017 and 2016, respectively. Other direct operating costs increased by $151,000 and $164,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The increase in 2018 and 2017 is due to operating costs incurred by the Company’s PBRT system and operating costs for the Company’s Gamma Knife site in Peru, which began treating patients in July 2017.

 

SELLING AND ADMINISTRATIVE EXPENSE

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Selling and administrative costs  $3,994    (7.6)%  $4,323    13.7%  $3,802 
Percentage of total revenue   20.3%        22.1%        20.3%

 

The Company's selling and administrative costs decreased $329,000 and increased $521,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The decrease in 2018 was driven by legal fees, severance expense incurred in 2017, and stock-based compensation incurred in 2017, related to performance awards. The increase in 2017 was driven by start-up costs for the Company’s new site in Peru, legal fees, consulting fees, travel costs, severance expense and building rent. The Company moved offices on August 31, 2016. Prior to the move, the Company subleased a portion of its existing office space. The Company also recorded approximately $108,000 of stock-based compensation expense to recognize performance awards for the year ended December 31, 2017. These performance awards had certain vesting targets tied to performance metrics which were achieved for the year ended.

 

INTEREST EXPENSE

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Interest expense  $1,631    (15.4)%  $1,927    12.9%  $1,707 
Percentage of total revenue   8.3%        9.9%        9.1%

 

The Company's interest expense decreased $296,000 and increased $220,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The decrease in 2018 compared to 2017 is primarily due to a lower average principal base for the Company’s lease and debt portfolio, effectively reducing interest expense. The increase in 2017 compared to 2016 is primarily due to interest incurred on PBRT lease financing, offset by a lower average principal base for the Company’s Gamma Knife portfolio, effectively reducing interest expense.

 

21

 

 

PROCEEDS RECEIVED FROM INVESTMENT IN EQUITY SECURITIES

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Proceeds received from investment in equity securities  $22    *  $0    *  $0 
                          
Percentage of total revenue   0.1%        0%        0.0%

*Not meaningful

 

Proceeds received from the Company’s investment in equity securities was $22,000 in 2018 compared to $0 in 2017 and 2016, respectively. As of December 31, 2017, the Company adjusted the carrying value of its investment in equity securities to the determined fair value of $0 and recorded a $579,000 impairment loss. Following a round of financing in the second quarter 2018, the Company’s investment in equity securities (preferred and common shares) was cancelled. The Company’s investment in common and preferred shares were valued at $0 and $22,000, respectively, resulting in cash proceeds of $22,000 from its investment in equity securities. The Company no longer has any ownership interest in the entity which is previously held an equity investment.

 

(LOSS) ON WRITE DOWN INVESTMENT IN EQUITY SECURITIES

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
(Loss) on write down investment in equity securities  $0    *  $(579)   *  $0 
                          
Percentage of total revenue   0.0%        (3.0)%        0.0%

*Not meaningful

 

(Loss) on the write down of the Company’s investment in equity securities was $0 in 2018 compared to $579,000 in 2017, and $0 in 2016. For 2017, the (loss) on the write down of investment in equity securities is due to the other-than-temporary assessment performed at December 31, 2017. The Company adjusted the carrying value of its investment in Mevion to the determined fair value of $0 and recorded a $579,000 impairment loss during the year ended December 31, 2017.

 

This transaction is treated as a capital loss for tax purposes which may be deducted only to the extent the Company has capital gains. The Company is not aware of any event or transaction planned where the Company would generate a capital gain. Therefore, a full valuation allowance was recorded against the income tax benefit from the impairment loss, and the net impact to the income tax provision is $0 for the year ended December 31, 2017.

 

(LOSS) ON EARLY EXTINGUISHMENT OF DEBT

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
(Loss) on early extinguishment of debt  $0    *  $0    *  $(108)
                          
Percentage of total revenue   0%        0%        (0.6)%

*Not meaningful

 

(Loss) on early extinguishment of debt was $0 in 2018 and 2017 compared to $0 and $108,000 in 2017 and 2016, respectively. In February 2016, the Company used a portion of the proceeds from the lease financing for its first MEVION S250 to pay down the $1,000,000 of Promissory Notes that were issued pursuant to the Note and Warrant Purchase Agreements (the “Agreements”) between the Company and four members of the Company’s Board of Directors. The Agreements permit for early payment without penalty to the Company. The Notes were issued with common stock warrants with an estimated fair value of $145,000. The unamortized balance of the discount on the Notes, of $80,000, and deferred fees incurred from the issuance of the Note of approximately $28,000, were recorded as a loss on early extinguishment of debt on the Company’s condensed consolidated statement of operations for the year ended December 31, 2016.

 

22

 

 

INTEREST AND OTHER INCOME

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Interest and other income  $198    6500.0%  $3    (80.0)%  $15 
                          
Percentage of total revenue   1.0%        0.0%        0.1%

 

Interest and other income increased $195,000 and decreased $12,000 in 2018 and 2017 compared to 2017 and 2016, respectively. The increase in 2018 was due to an insurance reimbursement received from the Company’s business interruption coverage. In the third quarter of 2018, the PBRT unit at Orlando Health sustained water damage resulting from the facility’s water evacuation system. The PBRT system was down for two weeks as a result. The Company received approximately $185,000. Interest and other income is generally comprised of interest expense and interest earned, and increases or decreases generally reflect fluctuations in these amounts.

 

INCOME TAX EXPENSE

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Income tax expense (benefit)  $451    

140.9

%  $(1,103)   (217.0)%  $943 
Percentage of total revenue   2.3%        (5.6)%        5.0%
Percentage of income, after net income attributable to non-controlling interests, and before income taxes   

30.6

%        (134.5)%        50.3%

 

Income tax expense increased $1,554,000 and decreased $2,046,000 in 2018 and 2017 compared to 2017 and 2016, respectively. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that is payable over eight years. The Tax Act also establishes new tax laws that will affect 2018 and later years, including, but not limited to, a reduction of the U.S. federal corporate tax rate from 34% to 21%, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, net operating loss deduction limitations, a base erosion, anti-tax abuse tax and a deduction for foreign-derived intangible income and a new provision designed to tax global intangible low-taxed income. As a result of the Tax Act, the Company revalued its federal and state deferred tax liabilities based on a 21% tax rate as opposed to a 34% tax rate. The net effect of this change on the Company’s income tax provision for the year ended December 31, 2017 was a tax benefit of $1,546,000. The increase for the year ended December 31, 2018 was due to the provision benefit recorded in 2017.

 

The Company anticipates that it will continue to record income tax expense if it operates profitably in the future. Currently there are state income tax payments required for most states in which the Company operates. At December 31, 2018, the Company is expected to utilize the remainder of its net operating loss carryforward for federal income tax return purposes.

 

23

 

 

NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS

 

(In thousands)  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Net income attributable to non-controlling interests  $607    (40.3)%  $1,017    (23.0)%  $1,320 
                          
Percentage of total revenue   3.1%        5.2%        7.1%

 

Net income attributable to non-controlling interests decreased $410,000 and $303,000 in 2018 and 2017 compared to 2017 and 2016, respectively. Net income attributable to non-controlling interests represents the pre-tax income earned by the 19% non-controlling interest in GKF, and the pre-tax income or losses of the non-controlling interests in various subsidiaries controlled by GKF. The decrease or increase in net income attributable to non-controlling interests reflects the relative profitability of GKF.

 

NET INCOME ATTRIBUTABLE TO AMERICAN SHARED HOSPITAL SERVICES

 

(In thousands,

except per share amounts)

  2018  

Increase

(Decrease)

   2017  

Increase

(Decrease)

   2016 
                     
Net income attributable to ASHS  $

1,023

    (46.8)%  $1,923    106.8%  $930 
Net income per share attributable to ASHS, diluted  $0.17    (48.5)%  $0.33    94.1%  $0.17 

 

Net income attributable to American Shared Hospital Services was $1,023,000 in 2018 compared to $1,923,000 in 2017, and $930,000 in 2016. Excluding the adjustment to the Company’s income tax provision, because of the Tax Act of $1,546,000, and the write-down of the Company’s investment in Mevion of $579,000 in 2017, net income in 2018 increased $45,000 compared to 2017. Excluding the adjustment to the Company’s income tax provision, because of the Tax Act of $1,546,000, and the write-down of the Company’s investment in Mevion of $579,000 in 2017, and the loss on early extinguishment of debt of $108,000, net of estimated taxes in 2016, net income decreased $38,000 in 2017 compared to 2016.

 

IMPAIRMENT ANALYSIS OF INVESTMENT IN EQUITY SECURITIES

 

As of December 31, 2018, and 2017 the Company had a $0 investment in the common stock of Mevion. The Company previously accounted for this investment under the cost method. The Company previously carried its investment in Mevion at cost and reviewed it for impairment on a quarterly basis, or as events or circumstances might have indicated that the carrying value of the investment may not be recoverable.

 

Based on guidance provided in Accounting Standards Codification (“ASC”) 320 Investments–Debt and Equity Securities (“ASC 320”) and Staff Accounting Bulletins (“SAB”) Topic 5M Other Than Temporary Impairment (“OTTI”) of Certain Investments in Equity Securities (“SAB Topic 5M”), the Company analyzed the related events of Mevion, that occurred in the second and third quarters of 2015 and its impact on the Company’s investment. The Company determined that these circumstances indicated a decline in value of its Mevion investment that was other-than-temporary and concluded that a write-down of the carrying value should be recognized. As of June 30, 2015, the Company adjusted its investment in Mevion to the estimated fair value of $600,000 and recorded a $2,114,000 impairment loss. The $2,114,000 other than temporary impairment of its investment in Mevion is recorded in other income (loss) on the Company’s Condensed Consolidated Statement of Operations.

 

24

 

 

During the period ended December 31, 2015, the Company engaged a third-party expert to review and corroborate its assessment of the fair value of the Mevion investment. Based on the third-party analysis, an additional impairment loss of $26,000 was recognized by the Company during the three months ended December 31, 2015. The fair value of the Company’s investment in Mevion, as of December 31, 2015 was approximately $579,000. The impairment loss for the year ended December 31, 2015 was $2,140,000.

 

During the year ended December 31, 2017, the Company reviewed its investment in Mevion and determined the fair value of its investment was $0. Based on the Company’s assessment of its investment in Mevion, the Company recognized an impairment loss for the year then ended December 31, 2017 of $579,000. During 2018, Mevion entered into a merger transaction with Mevion Medical Technology Group Limited, and the Company’s common shares in Mevion were cancelled.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company had cash and cash equivalents of $1,442,000 at December 31, 2018 compared to $2,152,000 at December 31, 2017, a decrease of $710,000. The Company’s expected primary cash needs on both a short and long-term basis are for capital expenditures, business expansion, working capital, and other general corporate purposes.

 

Operating activities provided cash of $8,062,000 in 2018, which was driven by net income of $1,630,000, non-cash charges for depreciation and amortization of $6,818,000, increased in deferred income tax of $48,000, net accrued interest on lease financing of $39,000, stock-based compensation expense of $223,000, and changes in other accrued liabilities and deferred revenue of $115,000. These were partially offset by changes in receivables of $420,000, changes in prepaid and other assets of $231,000, and net insurance proceeds receivable of $160,000.

 

The Company’s trade accounts receivable increased by $483,000 to $5,502,000 at December 31, 2018 from $5,019,000 at December 31, 2017, primarily due to accounts receivable related to the new PBRT system which began operations in April 2016. The number of days revenue (sales) outstanding (“DSO”) in accounts receivable as of December 31, 2018 increased to 102 days compared to 94 days at December 31, 2017. DSO can and does fluctuate depending on timing of customer payments received and the mix of fee per use versus retail customers. Retail sites generally have longer collection periods than fee per use sites.

 

Investing activities used $1,526,000 of cash in 2018 due to payments made towards the purchase of property and equipment of $1,577,000, offset by insurance proceeds of $51,000.

 

Financing activities used $7,246,000 of cash during 2018, primarily due to principal payments on long-term debt of $2,467,000, principal payments towards capital leases of $4,089,000, and distributions to non-controlling interests of $690,000.

 

The Company had working capital at December 31, 2018 of $472,000 compared to negative working capital of $114,000 at December 31, 2017. The $586,000 increase in net working capital was due to an increase in accounts receivable and other receivables of $506,000, increases in prepaid and other assets of $120,000, net receivable from insurance of $160,000, decreases in capital leases of $407,000 and decreases in long term debt of $340,000. This was offset by a decrease in cash of $710,000, increase in accounts payable of $76,000, increase in accrued liabilities of $141,000, and an increase in employee compensation and benefits of $20,000. The Company believes that its cash flow from cash on hand, operations, and other cash resources are adequate to meet its scheduled debt and capital lease obligations during the next 12 months. See additional discussion below related to commitments.

 

The Company, in the past, has secured financing for its Gamma Knife and radiation therapy units. The Company has secured financing for its projects from several lenders and anticipates that it will be able to secure financing on future projects from these or other lending sources, but there can be no assurance that financing will continue to be available on acceptable terms.

 

25

 

 

IMPACT OF INFLATION AND CHANGING PRICES

 

The Company does not believe that inflation has had a significant impact on operations because a substantial majority of the costs that it incurs under its customer contracts are fixed through the term of the contract.

 

CONTRACTUAL OBLIGATIONS, COMMITMENTS, CONTINGENT LIABILITIES AND OFF-BALANCE SHEET ARRANGEMENTS

 

The following table presents, as of December 31, 2018, the Company’s significant fixed and determinable contractual obligations by payment date. The payment amounts represent those amounts contractually due to the recipient and do not include any unamortized premiums or discounts, hedge basis adjustments, or other similar carrying value adjustments. Further discussion of the nature of each obligation is included in the notes to the consolidated financial statements referenced below.

 

For purposes of this table, these commitments are listed in the less than 1 year and 1-3-year categories.

 

   Payments Due by Period 
Contractual Obligations  Total amounts committed   Less than
1 year
   1-3 years   4-5 years   After
5 years
 
                          
Long-term debt (includes interest)  $6,168,000    2,396,000    2,352,000    668,000    752,000 
Capital leases (includes interest)   17,335,000    5,524,000    10,009,000    1,494,000    308,000 
Future equipment purchases   38,235,000    4,235,000    34,000,000    -    - 
Equipment service contracts   7,523,000    1,664,000    5,859,000    -    - 
Operating leases   1,208,000    275,000    509,000    424,000    - 
                          
Total contractual obligations  $70,469,000   $14,094,000   $52,729,000   $2,586,000   $1,060,000 

 

Further discussion of the long-term debt commitment is included in Note 5, capital leases in Note 6, and operating leases in Note 11 of the consolidated financial statements.

 

On December 20, 2018, the Company signed Second Amendments to two System Build Agreements (the “Amendments”) for the Company’s second and third Mevion PBRT units. The Company and Mevion have agreed to upgrade the second and third PBRT units for which the Company has purchase commitments. The Company is actively seeking sites for these units but, to date, has not entered into agreements with any party for either placement of a PBRT unit or the related financing. The Company projects that it will be required to commence delivery of the second and third PBRT units no later than 2023. In the event the Company is unable to enter into customer agreements within the requisite time frame or receive an extension from Mevion, the Company could forfeit its deposits.

 

As of December 31, 2018, the Company had commitments to purchase two MEVION S250i PBRT systems for $34,000,000 and the Company had $2,250,000 in non-refundable deposits toward the purchase of these two PBRT systems from Mevion Medical Systems, Inc. (“Mevion”). The non-refundable deposits are recorded in the Condensed Consolidated Balance Sheets as deposits and construction in progress.

 

As of December 31, 2018, the Company had commitments to perform three Cobalt-60 reloads at existing customer sites and purchase one LINAC system, to be placed at a new customer site in 2019. The Cobalt-60 reloads are scheduled to occur in 2019. Total Gamma Knife and LINAC commitments as of December 31, 2018 were $4,235,000. It is the Company’s intent to finance these commitments. There are no significant cash requirements, pending financing, for these commitments in the next 12 months. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company

 

26

 

 

On July 21, 2017, the Company entered into a Maintenance and Support Agreement (the “Mevion Service Agreement”) with Mevion, which provides for maintenance and support of the Company’s PBRT unit at Orlando Health. The Mevion Service Agreement began September 5, 2017 and renews annually. The agreement requires an annual prepayment of $1,285,000 which was made on August 6, 2018 for the current contractual period. This payment portion was recorded as a prepaid contract and will be amortized over the one-year service period. The Mevion Service Agreement is for a five (5) year period. On December 20, 2018, the Company signed a Second Amendment to the Mevion Service Agreement, where the Company agreed to increase the annual service payment by $250,000, effective for the second service year, and for each year thereafter, if a second Mevion PBRT unit is not placed at Orlando Health prior to September 2019. The Company has accrued the pro-rata portion of this additional maintenance expense for the year ended December 31, 2018.

 

As of December 31, 2018, the Company had commitments to service and maintain its Gamma Knife and PBRT equipment. The service commitments are carried out via contracts with Mevion and Elekta AB. The Company’s commitment to purchase a LINAC in 2019 includes a 9-year agreement to service the equipment. Total service commitments as of December 31, 2018 were $7,523,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

 

The Company estimates the following commitments for each of the equipment systems, with expected timing of payments as follows as of December 31, 2018:

 

   2019   Thereafter   Total 
Proton Beam Units  $-   $34,000,000   $34,000,000 
                
Gamma Knife & Linac Units   4,235,000    -    4,235,000 
                
Service Contracts   1,664,000    5,859,000    7,523,000 
                
Total Commitments  $5,899,000   $39,859,000   $45,758,000 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The table below presents information about certain market-sensitive financial instruments as of December 31, 2018. The fair values were determined based on quoted market prices for the same or similar instruments.

 

   Payments Due by Period   There-        Fair 
(amounts in thousands)  2019   2020   2021   2022   2023   after   Total   Value 
                                 
Fixed rate long-term debt and present value of capital leases  $6,526   $4,567   $6,143   $1,156   $773   $1,000   $20,165   $20,277 
                                         
Average interest rates   8.0%   8.5%   9.0%   6.6%   6.1%   6.2%   8.1%     

 

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

 

At December 31, 2018, we had no significant long-term, market-sensitive investments.

 

We have no affiliation with partnerships, trusts or other entities whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements, and therefore have no exposure to the financing, liquidity, market or credit risks associated with such entities.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See the Index to Consolidated Financial Statements and Financial Statement Schedules included at page A-1 of this report.

 

27

 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

(a)Evaluation of disclosure controls and procedures.

 

Our Chief Executive Officer and our Chief Financial Officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (“Exchange Act”) Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this annual report, have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

 

(b)Management’s report on internal control over financial reporting.

 

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control system was designed to provide reasonable assurance to its management and Board of Directors regarding the preparation and fair presentation of published financial statements.

 

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control – Integrated Framework (2013). Based on this assessment management believes that, as of December 31, 2018, the Company’s internal control over financial reporting is effective based on those criteria.

 

(c)Changes in internal controls over financial reporting.

 

Our Chief Executive Officer and our Chief Financial Officer have evaluated the changes to the Company’s internal control over financial reporting that occurred during our last fiscal quarter ended December 31, 2018, as required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15, and have concluded that there were no such changes that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Information regarding directors is incorporated herein by reference from the Company’s definitive Proxy Statement for the 2019 Annual Meeting of Shareholders (the “2019 Proxy Statement”). Information regarding executive officers of the Company, included herein under the caption “Executive Officers of the Company” in Part I, Item 1 above, is incorporated herein by reference.

 

28

 

 

Information concerning the identification of our standing audit committee required by this Item is incorporated by reference from the 2019 Proxy Statement.

 

Information concerning our audit committee financial experts required by this Item is incorporated by reference from the 2019 Proxy Statement.

 

Information concerning compliance with Section 16(a) of the Exchange Act required by this Item is incorporated by reference from the 2019 Proxy Statement.

 

We have adopted a Code of Ethics that is available on our website at www.ashs.com. The information on our website is not part of this report. You may also request a copy of this document free of charge by writing our Corporate Secretary.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Information required by this Item is incorporated herein by reference from the 2019 Proxy Statement.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Information required by this Item is incorporated herein by reference from the 2019 Proxy Statement.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Information required by this Item is incorporated herein by reference from the 2019 Proxy Statement.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

Information required by this Item is incorporated herein by reference from the 2019 Proxy Statement.

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)Financial Statements and Schedules.

 

The following Financial Statements and Schedules are filed with this Report:

Report of Independent Registered Public Accounting Firm

Audited Consolidated Financial Statements

Consolidated Balance Sheets

Consolidated Statements of Operations

Consolidated Statements of Comprehensive Income (Loss)

Consolidated Statements of Shareholders' Equity

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements

Financial Statement Schedules- no schedules are included since the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the financial statements and notes thereto.

 

(b)Exhibits.

 

The following Exhibits are filed with this Report.

 

29

 

 

Exhibit           Incorporated by reference herein
Number       Description   Form   Exhibit   Date

3.1     Articles of Incorporation of the Company.   10-Q
001-08789
  3.1   5/15/2017
3.1a     Articles of Incorporation of the Company, as amended.   10-K
001-08789
  3.1   3/27/2017
3.2       By-laws of the Company, as amended and restated dated as of June 21, 2016.   10-Q
001-08789
  3.2   5/15/2017 

 

4.1       Rights Agreement dated as of March 22, 1999 between American Shared Hospital Services and American Stock Transfer & Trust Company, as Rights Agent.   8-K
001-08789
  4   4/1/1999
                     
4.1a       First Amendment to Rights Agreement dated as of March 12, 2009 between American Shared Hospital Services and American Stock Transfer & Trust Company, as Rights Agent.   8-K
001-08789
  3.1   3/13/2009
                     
10.1       Operating Agreement for GK Financing, LLC dated as of October 17, 1995 between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   S-1
033-63721
  10.12   10/26/1995
                     
10.1a       Amendment Agreement dated as of October 26, 1995 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   S-1/A
033-63721
  10.13   3/29/1996
                     
10.1b       Second Amendment Agreement dated as of December 20, 1995 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   S-1/A
033-63721
  10.13   3/29/1996
                     
10.1c       Third Amendment Agreement dated as of October 16, 1996 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.13b   3/31/1998
                     
10.1d       Fourth Amendment Agreement dated as of March 31, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.8   3/31/1999

 

30

 

 

10.1e       Fifth Amendment Agreement dated as of March 31, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.9   3/31/1999
                     
10.1f       Sixth Amendment Agreement dated as of June 5, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.10   3/31/1999
                     
10.1g       Seventh Amendment Agreement dated as of October 18, 2006 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.52   4/2/2007
                     
10.1h       Eighth Amendment Agreement dated as of April 28, 2010 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.1h   3/30/2016
                     
10.1i       Ninth Amendment Agreement dated as of May 16, 2011 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.   10-K
001-08789
  10.1i   3/30/2016
                     
10.2       Lease Agreement for a Gamma Knife Unit dated as of October 29, 1996 between GK Financing, LLC and Methodist Healthcare Systems of San Antonio, Ltd., dba Southwest Texas Methodist Hospital.   10-K
001-08789
  10.2   3/30/2016
                     
10.2a       Addendum to Lease Agreement for a Gamma Knife Unit dated as of October 31, 1996 between GK Financing, LLC and Methodist Healthcare System of San Antonio, Ltd., dba Southwest Texas Methodist Hospital.     10-K
001-08789
  10.2a   3/30/2016
                     
10.2b       Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of October 16, 1997 between Methodist Healthcare System of San Antonio, Ltd., d.b.a. Southwest Texas Methodist Hospital and GK Financing, LLC.   10-K
001-08789
  10.2b   3/30/2016

 

31

 

 

10.2c       Amendment to Lease Agreement for a Gamma Knife Unit dated as of December 13, 2003 between Methodist Healthcare Systems of San Antonio, Ltd., d/b/a Southwest Texas Methodist Hospital and GK Financing, LLC.   10-K
001-08789
  10.2c   3/30/2016
                     
10.2d   #   Second Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated as of December 23, 2009 between GK Financing, LLC and Methodist Healthcare Systems of San Antonio, Ltd., d/b/a Southwest Texas Methodist Hospital.     10-Q
001-08789
  10.18b   11/15/2010
                     
10.3       Lease Agreement for a Gamma Knife Unit dated as of April 10, 1997 between GK Financing, LLC and Yale-New Haven Ambulatory Services Corporation.   10-K
001-08789
  10.3   3/30/2016
                     
10.3a       Addendum to Lease Agreement for a Gamma Knife Unit dated as of October 25, 2005 between Yale-New Haven Ambulatory Services Corporation and GK Financing, LLC.      10-K
001-08789
  10.3a   3/30/2016
                     
10.3b       Assignment, Assumption, and Amendment to Lease Agreement for a Gamma Knife Unit dated as of June 30, 2006 between Yale-New Haven Ambulatory Services Corporation, Yale-New Haven Hospital, Inc. a/k/a Yale-New Haven Hospital, and GK Financing, LLC.   10-K
001-08789
  10.3b   3/30/2016

                     
10.3c       Second Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated as of May 15, 2009 between Yale-New Haven Hospital, Inc. a/k/a Yale-New Haven Hospital and GK Financing, LLC.   10-Q
001-08789
  10.2   11/13/2017

 

                     
10.3d       Third Amendment to Lease Agreement for a Gamma Knife Unit dated as of July 1, 2014 between Yale-New Haven Hospital, Inc. a/k/a Yale-New Haven Hospital and GK Financing, LLC.   10-Q
001-08789
  10.19c   11/14/2014
                     
10.4       Purchased Services Agreement (for a Gamma Knife Unit) dated as of November 19, 2008 between GK Financing, LLC and Kettering Medical Center.   10-Q
001-08789
  10.1   8/11/2016

 

32

 

 

10.4a       First Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of June 11, 2009 between GK Financing, LLC and Kettering Medical Center.     10-Q
001-08789
  10.1a   8/11/2016
                     
10.4b   #   Second Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of February 27, 2014 between GK Financing, LLC and Kettering Medical Center.   10-K
001-08789
  10.21c   4/1/2015
                     
10.5   #   Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated as of July 30, 2013 between Tufts Medical Center, Inc. (FKA New England Medical Center Hospitals, Inc.) and GK Financing, LLC.   10-K
001-08789
  10.22b   3/31/2014
                     
10.6   #   Amended and Restated Equipment Lease Agreement (for a Gamma Knife Unit) dated as of December 12, 2014, between GK Financing, LLC and the Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences.   10-Q
001-08789
  10.4   8/19/2015
                     
10.7       Lease Agreement for a Gamma Knife Unit dated as of May 28, 1999 between GK Financing, LLC and Froedtert Memorial Lutheran Hospital.     10-K
001-08789
  10.7   3/30/2016
                     
10.7a       Addendum dated as of June 24, 1999 to Lease Agreement for a Gamma Knife Unit between GK Financing, LLC and Froedtert Memorial Lutheran Hospital.   10-K
001-08789
  10.27   3/29/2000
                     
10.7b       Amendment dated as of July 12, 1999 to Lease Agreement for a Gamma Knife Unit between GK Financing, LLC and Froedtert Memorial Lutheran Hospital.   10-K
001-08789
  10.28   3/29/2000
                     
10.7c       Amendment dated as of August 24, 1999 to Lease Agreement for a Gamma Knife Unit between GK Financing, LLC and Froedtert Memorial Lutheran Hospital.  

10-K

001-08789

  10.29   3/29/2000
                     
10.7d       First Amendment to Lease Agreement for a Gamma Knife Unit dated as of December 29, 2008 between GK Financing, LLC and Froedtert Memorial Lutheran Hospital.     10-K
001-08789
  10.7d   3/30/2016

 

33

 

 

10.7e       Second Amendment to Lease Agreement for a Gamma Knife Unit dated as of May 16, 2013 between GK Financing, LLC and Froedtert Memorial Lutheran Hospital, Inc.   10-K
001-08789
  10.7e   3/30/2016
                     
10.7f       Third Amendment to Lease Agreement for a Gamma Knife Unit dated as of December 15, 2014 between GK Financing, LLC and Froedtert Memorial Lutheran Hospital, Inc.   10-K
001-08789
  10.26c   4/1/2015
                     
10.8       Lease Agreement for a Gamma Knife Unit dated as of December 11, 1996 between GK Financing, LLC and The Community Hospital Group, Inc., dba JFK Medical Center.     10-K
001-08789
  10.8   3/30/2016
                     
10.8a       Addendum One to Lease Agreement for a Gamma Knife Unit dated on January 9, 2008 and effective as of July 1, 2002  between The Community Hospital Group, Inc., dba JFK Medical Center and GK Financing, LLC.   10-K
001-08789
  10.8a   3/30/2016
                     
10.8b       Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of January 9, 2008 between The Community Hospital Group, Inc., dba JFK Medical Center and GK Financing, LLC.   10-K
001-08789
  10.8b   3/30/2016
                     
10.8c       Addendum Three to Lease Agreement for a Gamma Knife Unit dated as of April 25, 2015, between The Community Hospital Group, Inc., dba JFK Medical Center and GK Financing, LLC.   10-Q
001-08789
  10.5   8/19/2015
                     
10.8d       Addendum Four to Lease Agreement for a Gamma Knife Unit dated as of April 25, 2016 between The Community Hospital Group, Inc., dba JFK Medical Center and GK Financing, LLC.   10-Q
001-08789
  10.1   5/15/2017
                     
10.8e       Addendum Five to Lease Agreement for a Gamma Knife Unit dated as of April 25, 2017 between The Community Hospital Group, Inc., dba JFK Medical Center and GK Financing, LLC   10-Q
001-08789
  10.1   8/9/2018

 

34

 

 

10.9       Lease Agreement for a Gamma Knife Unit dated as of June 3, 1999 between GK Financing, LLC and Sunrise Hospital and Medical Center, LLC d/b/a Sunrise Hospital and Medical Center.   10-K
001-08789
  10.9   3/30/2016
                     
10.9a       Addendum to Lease Agreement for a Gamma Knife Unit dated as of December 1, 1998 between Sunrise Hospital and Medical Center, LLC d/b/a Sunrise Hospital and Medical Center and GK Financing, LLC.   10-K
001-08789
  10.9a   3/30/2016
                     
10.9b       Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of January 17, 2007 between GK Financing, LLC and Sunrise Hospital Medical Center, LLC d/b/a Sunrise Hospital Medical Center.   10-K
001-08789
  10.9b   3/30/2016
                     
10.9c       Addendum Three to Lease Agreement for a Gamma Knife Unit dated as of June 20, 2007 between GK Financing, LLC and Sunrise Hospital and Medical Center, LLC d/b/a Sunrise Hospital and Medical Center.     10-K
001-08789
  10.9c   3/30/2016
                     
10.9d       Addendum Four to Lease Agreement for a Gamma Knife Unit dated as of February 8, 2010 between GK Financing, LLC and Sunrise Hospital and Medical Center, LLC d/b/a Sunrise Hospital and Medical Center.   10-K
001-08789
  10.9d   3/30/2016
                     
10.9e   #   Addendum Five to Lease Agreement for a Gamma Knife Unit dated as of May 18, 2012 between GK Financing, LLC and Sunrise Hospital and Medical Center, LLC d/b/a Sunrise Hospital and Medical Center.   10-Q
001-08789
  10.66   11/14/2013
                     
10.10       Lease Agreement for a Gamma Knife Unit dated as of November 1, 1999 between GK Financing, LLC and Jackson HMA, Inc. d/b/a Central Mississippi Medical Center.     10-K
001-08789
  10.10   3/30/2016
                     
10.10a       Addendum to Lease Agreement for a Gamma Knife Unit dated as of November 1, 1999 between Jackson HMA, Inc. dba Central Mississippi Medical Center and GK Financing, LLC.   10-Q
001-08789
  10.34   8/10/2001

 

35

 

 

10.10b   #   Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of November 6, 2006 between GK Financing, LLC and Jackson HMA, Inc. d/b/a Central Mississippi Medical Center.   10-K
001-08789
  10.51   4/2/2007
                     
10.10c       Amendment Three to Lease Agreement for a Gamma Knife Unit dated as of February 23, 2010 between GK Financing, LLC and Jackson HMA, LLC d/b/a Central Mississippi Medical Center.   10-K
001-08789
  10.10c   3/30/2016
                     
10.11       Lease Agreement for a Gamma Knife Unit dated as of February 18, 2000 between GK Financing, LLC and OSF HealthCare System.     10-K
001-08789
  10.11   3/30/2016
                     
10.11a       Addendum to Lease Agreement for a Gamma Knife Unit dated as of April 13, 2007, between GK Financing, LLC and OSF Healthcare System.   10-Q
001-08789
  10.2   8/11/2016
                     
10.11b       Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of October 31, 2012 between GK Financing, LLC and OSF Healthcare System.   10-Q
001-08789
  10.2a   8/11/2016
                     
10.11c   #   Addendum Three to Lease Agreement for a Gamma Knife Unit dates as of June 7, 2016 between GK Financing, LLC and OSF Healthcare System.   10-Q
001-08789
  10.2b   8/11/2016
                     
10.12       Equipment Lease Agreement (for a Gamma Knife Unit) dated as of September 13, 2001 between GK Financing, LLC and Mercy Medical Center.     10-K
001-08789
  10.12   3/30/2016
                     
10.12a       Amendment Number One to Equipment Lease Agreement (for a Gamma Knife Unit) dated as of September 13, 2001 between GK Financing, LLC and Mercy Medical Center.     10-Q
001-08789
  10.41   11/14/2002
                     
10.13       Equipment Lease Agreement (for a Gamma Knife Unit) dated as of February 13, 2003 between GK Financing, LLC and AHS Albuquerque Regional Medical Center, LLC.   10-K
001-08789
  10.13   3/30/2016

 

36

 

 

10.13a   #   Amendment to Equipment Lease Agreement (Perfexion Upgrade) dated as of April 8, 2011 between GK Financing, LLC and Lovelace Health System, Inc., d/b/a Lovelace Medical Center.     10-Q
001-08789
  10.62   8/15/2011
                     
10.13b       Assignment and Assumption of Purchase and License Agreement dated as of February 2, 2011 between Elekta, Inc., GK Financing, LLC and Albuquerque GK Equipment, LLC.   10-Q
001-08789
  10.62a   8/15/2011
                     
10.14       Equipment Lease Agreement (for a Gamma Knife Unit) dated as of March 21, 2003 between GK Financing, LLC and Northern Westchester Hospital Center.   10-K
001-08789
  10.14   3/30/2016
                     
10.14a   #   Amendment to Equipment Lease Agreement (Perfexion Upgrade) dated as of June 8, 2012 between GK Financing, LLC and Northern Westchester Hospital Center.   10-Q
001-08789
  10.46a   8/14/2013
                     
10.15       Equipment Lease Agreement (for a Gamma Knife Unit) dated as of May 28, 2004 between GK Financing, LLC and Mercy Health Center.     10-K
001-08789
  10.15   3/30/2016
                     
10.15a       Addendum One to Equipment Lease Agreement (for a Gamma Knife Unit) dated as of December 23, 2011 between Mercy Health Center and GK Financing, LLC.     10-K
001-08789
  10.15a   3/30/2016
                     
10.15b       Addendum Two to Equipment Lease Agreement (for a Gamma Knife Unit) dated as of July 31, 2015, between Mercy Hospital Oklahoma City, Inc. and GK Financing, LLC.   10-Q
001-08789
  10.1   11/12/2015

                     
10.15c       Addendum Three to Equipment Lease Agreement (for a Gamma Knife Unit) dated as of September 3, 2016, between Mercy Hospital Oklahoma City, Inc. and GK Financing, LLC.   10-K
001-08789
  10.15c   3/27/2017
                     
10.15d       Addendum Four to Equipment Lease Agreement (for a Gamma Knife Unite) dated as of May 1, 2017 between Mercy Hospital Oklahoma City, Inc. and GK Financing, LLC.   10-Q
001-08789
  10.1   8/10/2017

 

                     
10.16   #   Purchased Services Agreement (for a Gamma Knife Unit) dated as of March 5, 2008 between GK Financing, LLC and USC University Hospital, Inc.   10-Q
001-08789
  10.57   5/14/2008

 

37

 

 

10.16a   #   First Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of April 1, 2009 between GK Financing, LLC and University of Southern California.   10-Q
001-08789
  10.57a   8/14/2009
                     
10.16b   #   Second Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of October 1, 2013 between GK Financing, LLC and University of Southern California.   10-Q
001-08789
  10.57b   8/14/2014
                     
10.17   #   Equipment Lease Agreement (for a Gamma Knife Unit) dated as of May 1, 2010 between GK Financing, LLC and Fort Sanders Regional Medical Center.     10-Q
001-08789
  10.60   5/16/2011
                     
10.17a       Amendment to Lease Agreement (for a Gamma Knife Unit) dated as of January 3, 2012 between GK Financing, LLC and Fort Sanders Regional Medical Center.   10-K
001-08789
  10.17a   3/30/2016
                     
10.17b       Second Amendment to Equipment Lease Agreement (for a Gamma Knife Unit) dated as of June 1, 2017 between GK Financing, LLC and Fort Sanders Regional Medical Center   10-Q
001-08789
  10.2   8/10/2017
                     
10.18   #   Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of August 5, 2011 between Jacksonville GK Equipment, LLC and St. Vincent’s Medical Center, Inc.   10-K
001-08789
  10.63   3/30/2012
                     
10.18a   #   First Amendment to the Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of October 10, 2011 between Jacksonville GK Equipment, LLC and St. Vincent’s Medical Center, Inc.   10-K
001-08789
  10.63a   3/30/2012
                     
10.19   #   Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of January 19, 2012 between GK Financing, LLC and Sacred Heart Health System, Inc.   10-Q
001-08789
  10.65   5/15/2013
                     
10.20   #   Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of March 27, 2014 between GK Financing, LLC and PeaceHealth doing business through its operating division PeaceHealth Sacred Heart Medical Center at RiverBend.   10-K
001-08789
  10.67   4/1/2015
                     
10.21   #   Equipment Lease Agreement (for a Gamma Knife Unit) dated as of February 21, 2017 between Bryan Medical Center, and GK Financing, LLC.   10-Q
001-08789
  10.1   11/13/2017

 

38

 

 

10.21a   #   First Amendment to Equipment Lease Agreement (for a Gamma Knife unit) dated as of February 14, 2018 between Bryan Medical Center and GK Financing, LLC   10-Q
001-08789
  10.1   5/10/2018

 

10.22   #   Proton Beam Radiation Therapy Lease Agreement dated as of October 18, 2006 between American Shared Hospital Services and Orlando Regional Healthcare System, Inc.   10-Q
001-08789
  10.3   8/11/2016
                     
10.22a   #   Amendment One to Proton Beam Radiation Therapy Lease Agreement dated as of August 12, 2012 between American Shared Hospital Services and Orlando Health, Inc., formerly known as Orlando Regional Healthcare System, Inc.   10-Q
001-08789
  10.3a   8/11/2016
                     
10.23     American Shared Hospital Services Incentive Compensation Plan as Amended and Restated effective June 27, 2017.   10-Q
001-08789
  10.2   8/9/2018

                     
10.25     Form of Indemnification Agreement between American Shared Hospital Services and members of its Board of Directors.   10-K
001-08789
  10.26   3/30/2016
                     
10.26     Form of American Shared Hospital Services Incentive Compensation Plan Performance Share Award Agreement.   10-K
001-08789
  10.25   3/27/2017

                     
21.1   *   Subsidiaries of American Shared Hospital Services            
                     
23.1   *   Consent of Independent Registered Public Accounting Firm            
                     
31.1   *   Certification of Chief Executive Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            
                     
31.2   *   Certification of Chief Financial Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            

 

39

 

 

32.1   ǂ   Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            

 

101.INS   *   XBRL Instance Document
101.SCH   *   XBRL Taxonomy Extension Schema Document
101.CAL   *   XBRL Taxonomy Calculation Linkbase Document
101.DEF   *   XBRL Taxonomy Definition Linkbase Document
101.LAB   *   XBRL Taxonomy Label Linkbase Document
101.PRE   *   XBRL Taxonomy Extension Presentation Linkbase Document

 

  * Filed herewith.
  ǂ Furnished herewith.
  # Confidential material appearing in this document has been omitted and filed separately with the Securities and Exchange Commission in accordance with Rule 24b-2, promulgated under the Securities and Exchange Act of 1934, as amended.  Omitted information has been replaced with asterisks.
  Indicates management compensatory plan, contract, or arrangement.

 

ITEM 16. FORM 10-K SUMMARY

 

The Optional summary in Item 16 has not been included in this Form 10-K.

 

40

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AMERICAN SHARED HOSPITAL SERVICES
  (Registrant)
     
March 29, 2019 By: /s/ Ernest A. Bates, M.D.
    Ernest A. Bates, M.D.
    Chairman of the Board and
    Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Ernest A. Bates   Chairman of the Board and   March 29, 2019
Ernest A. Bates, M.D.   Chief Executive Officer    
    (Principal Executive Officer)    
         
/s/ Daniel G. Kelly Jr.   Director   March 29, 2019
Daniel G. Kelly JR.        
         
/s/ David A. Larson   Director   March 29, 2019
David A. Larson, M.D.        
         
/s/ Sandra A. J. Lawrence   Director   March 29, 2019
Sandra A. J. Lawrence        
         
/s/ S. Mert Ozyurek   Director   March 29, 2019
S. Mert Ozyurek        
         
/s/ John F. Ruffle   Director   March 29, 2019
John F. Ruffle        
         
/s/ Raymond C. Stachowiak   Director   March 29, 2019
Raymond C. Stachowiak        
         
/s/ Stanley S. Trotman, Jr.   Director   March 29, 2019
Stanley S. Trotman, Jr.        
         
/s/ Craig K. Tagawa   Chief Operating Officer and   March 29, 2019
Craig K. Tagawa   Chief Financial Officer    
    (Principal Accounting Officer)    

 

41

 

 

AMERICAN SHARED HOSPITAL SERVICES

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

and

CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF DECEMBER 31, 2018 and 2017,

and

FOR THE THREE YEARS ENDED DECEMBER 31, 2018

 

 

 

 

Contents

 

  PAGE
   
Report of Independent Registered Public Accounting Firm F-3
   
Consolidated Financial Statements  
Balance sheets F-4
Statements of operations F-5
Statement of shareholders’ equity F-6
Statements of cash flows F-7
Notes to financial statements F-8 – F-27

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and the Board of Directors of

American Shared Hospital Services, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of American Shared Hospital Services, Inc. (the “Company”) as of December 31, 2018 and 2017, and the related consolidated statements of operations, stockholders’ equity and cash flows for the three years ended December 31, 2018. In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2018 and 2017, and the consolidated results of its operations and its cash flows for the three years ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

basis for our opinion.

 

/s/ Moss Adams LLP

 

San Francisco, CA

March 29, 2019

 

We have served as the Company’s auditor since 1999.

 

F-3

 

 

American Shared Hospital Services
Consolidated Balance sheets

 

   DECEMBER 31, 
   2018   2017 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $1,442,000   $2,152,000 
Restricted cash   350,000    350,000 
Trade accounts receivable, net of allowance for doubtful accounts of $100,000 at December 31, 2018 and December 31, 2017   5,502,000    5,019,000 
Other receivables insurance proceeds   1,137,000    - 
Other receivables   239,000    216,000 
Prepaid expenses and other current assets   1,276,000    1,156,000 
Total current assets   9,946,000    8,893,000 
PROPERTY AND EQUIPMENT, net   46,694,000    48,491,000 
OTHER ASSETS   862,000    792,000 
TOTAL ASSETS  $57,502,000   $58,176,000 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $435,000   $359,000 
Employee compensation and benefits   207,000    187,000 
Other accrued liabilities   1,329,000    1,188,000 
Other accrued liabilities insurance payable   977,000    - 
Current portion of long-term debt   2,119,000    2,459,000 
Current portion of capital leases   4,407,000    4,814,000 
Total current liabilities   9,474,000    9,007,000 
LONG-TERM DEBT, less current portion   3,332,000    3,598,000 
LONG-TERM CAPITAL LEASES, less current portion   10,308,000    12,272,000 
DEFERRED REVENUE, less current portion   382,000    504,000 
DEFERRED INCOME TAXES   2,958,000    2,910,000 
COMMITMENTS AND CONTINGENCIES (See Note 11)          
SHAREHOLDERS’ EQUITY          
Common stock, no par value          
Common stock, no par value (10,000,000 authorized;  Issued and outstanding shares – 5,714,000 at December 31, 2018 and 5,710,000 at December 31, 2017   10,711,000    10,711,000 
Additional paid-in capital   6,495,000    6,272,000 
Retained earnings   7,896,000    6,873,000 
Total equity- American Shared Hospital Services   25,102,000    23,856,000 
Non-controlling interests in subsidiaries   5,946,000    6,029,000 
Total shareholders’ equity   31,048,000    29,885,000 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY  $57,502,000   $58,176,000 

 

See accompanying notes

 

F-4

 

 

American Shared Hospital Services
Statements of operations

 

   YEARS ENDED DECEMBER 31, 
   2018   2017   2016 
Revenues:               
Rental income from medical services  $19,714,000   $19,556,000   $18,700,000 
    19,714,000    19,556,000    18,700,000 
Costs of revenue:               
Maintenance and supplies   2,399,000    1,359,000    874,000 
Depreciation and amortization   6,745,000    6,601,000    6,262,000 
Other direct operating costs   3,084,000    2,933,000    2,769,000 
    12,228,000    10,893,000    9,905,000 
Gross margin   7,486,000    8,663,000    8,795,000 
Selling and administrative expense   3,994,000    4,323,000    3,802,000 
Interest expense   1,631,000    1,927,000    1,707,000 
Operating income   1,861,000    2,413,000    3,286,000 
Proceeds received from investment in equity securities   22,000    -    - 
(Loss) on write down of investment in equity securities   -    (579,000)   - 
(Loss) on early extinguishment of debt   -    -    (108,000)
Interest and other income   198,000    3,000    15,000 
Income before income taxes   2,081,000    1,837,000    3,193,000 
Income tax expense (benefit)   451,000    (1,103,000)   943,000 
Net income   1,630,000    2,940,000    2,250,000 
Less: net income attributable to non-controlling interests   (607,000)   (1,017,000)   (1,320,000)
Net income attributable to American Shared Hospital Services  $1,023,000   $1,923,000   $930,000 
                
Net income per share attributable to American Shared Hospital Services:               
Income per common share- basic  $0.18   $0.33   $0.17 
Income per common share- diluted  $0.17   $0.33   $0.17 

 

See accompanying notes

 

F-5

 

 

American Shared Hospital Services
Consolidated Statement of Shareholders’ Equity

 

   THREE YEARS ENDED DECEMBER 31, 2018 
           Additional           Non-controlling     
   Common   Common   Paid-in   Retained   Sub-Total   Interests in     
   Shares   Stock   Capital   Earnings   ASHS   Subsidiaries   Total 
Balances at January 1, 2016   5,364,000  $10,376,000   $5,734,000   $4,020,000   $20,130,000   $5,050,000   $25,180,000 
Stock-based compensation expense   4,000    -    215,000    -    215,000    -    215,000 
Proceeds from warrants exercised   100,000    220,000    -    -    220,000    -    220,000 
Non-controlling interest investment in subsidiaries   -    -    -    -    -    7,000    7,000 
Cash distributions to non-controlling interests   -    -    -    -    -    (699,000)   (699,000)
Net income   -    -    -    930,000    930,000    1,320,000    2,250,000 
Balances at January 1, 2017   5,468,000   $10,596,000   $5,949,000   $4,950,000   $21,495,000   $5,678,000   $27,173,000 
Stock-based compensation expense   4,000    -    323,000    -    323,000    -    323,000 
Restricted stock awards   162,000    -    -    -    -    -    - 
Warrants and options exercised   76,000    115,000    -    -    115,000    -    115,000 
Cash distributions to non-controlling interests   -    -    -    -    -    (666,000)   (666,000)
Net income   -    -    -    1,923,000    1,923,000    1,017,000    2,940,000 
Balances at December 31, 2017   5,710,000   $10,711,000   $6,272,000   $6,873,000   $23,856,000   $6,029,000   $29,885,000 
Stock-based compensation expense   4,000    -    223,000    -    223,000    -    223,000 
Cash distributions to non-controlling interests   -    -    -    -    -    (690,000)   (690,000)
Net income   -    -    -    1,023,000    1,023,000    607,000    1,630,000 
Balances at December 31, 2018   5,714,000   $10,711,000   $6,495,000   $7,896,000   $25,102,000   $5,946,000   $31,048,000 

 

See accompanying notes

 

F-6

 

 

American Shared Hospital Services
Consolidated Statements of Cash Flows

 

   YEARS ENDED DECEMBER 31, 
   2018   2017   2016 
             
OPERATING ACTIVITIES               
Net income  $1,630,000   $2,940,000   $2,250,000 
Adjustments to reconcile net income to net cash from operating activities:               
Depreciation and amortization   6,818,000    6,677,000    6,327,000 
Loss on disposal of assets   -    15,000    - 
Loss on early extinguishment of debt   -    -    108,000 
Loss on write down investment in equity securities   -    579,000    - 
Amortization of accrued interest on lease financing   -    80,000    - 
Deferred income tax expense (benefit)   48,000    (1,266,000)   772,000 
Accrued interest on lease financing   39,000    33,000    414,000 
Stock-based compensation expense   223,000    323,000    215,000 
Other non-cash items   -    -    4,000 
Changes in operating assets and liabilities:               
Receivables   (420,000)   (860,000)   (1,230,000)
Prepaid expenses and other assets   (231,000)   (793,000)   (283,000)
Accounts payable, accrued liabilities and deferred revenue   115,000    125,000    (199,000)
Net insurance proceeds receivable   (160,000)   -    - 
Net cash from operating activities   8,062,000    7,853,000    8,378,000 
INVESTING ACTIVITIES               
Payment for purchase of property and equipment   (1,577,000)   (803,000)   (1,042,000)
Proceeds from insurance   51,000    -    - 
Proceeds from sale of equipment   -    150,000    - 
Net cash (used in) investing activities   (1,526,000)   (653,000)   (1,042,000)
FINANCING ACTIVITIES               
Principal payments on long-term debt   (2,467,000)   (2,314,000)   (2,968,000)
Principal payments on capital leases   (4,089,000)   (4,954,000)   (4,171,000)
Capital contributions from non-controlling interests   -    -    7,000 
Distributions to non-controlling interests   (690,000)   (666,000)   (699,000)
Proceeds from warrants and options exercised   -    115,000    220,000 
Proceeds from capital lease financing for reimbursement of payments for acquisition of equipment   -    -    1,137,000 
Net cash (used in) financing activities   (7,246,000)   (7,819,000)   (6,474,000)
Net change in cash and cash equivalents   (710,000)   (619,000)   862,000 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year   2,502,000    3,121,000    2,259,000 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year  $1,792,000   $2,502,000   $3,121,000 
                
SUPPLEMENTAL CASH FLOW DISCLOSURE               
Cash paid for interest  $1,727,000   $1,712,000   $2,150,000 
Cash paid for income taxes  $459,000   $126,000   $266,000 
                
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES               
Acquisition of equipment with capital lease financing  $1,679,000   $2,153,000   $8,878,000 
Acquisition of equipment with long-term debt financing  $1,853,000   $992,000   $570,000 
Insurance proceeds receivable and due  $977,000   $-   $- 

 

See accompanying notes

 

F-7

 

 

American Shared Hospital Services
Notes to Consolidated Financial Statements

 

Note 1 – Business and Basis of Presentation

 

Business These consolidated financial statements include the accounts of American Shared Hospital Services (the “Company”) and its subsidiaries as follows: The Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”) , PBRT Orlando, LLC (“Orlando”), OR21, Inc., and MedLeader.com, Inc. (“MedLeader”). The Company is also the majority owner of Long Beach Equipment, LLC (“LBE”). ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”). GKF is also the majority-owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”), and Jacksonville GK Equipment, LLC (“JGKE”).

 

The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. During 2018 GKF provided Gamma Knife units to sixteen medical centers in the United States in the states of Arkansas, California, Florida, Illinois, Massachusetts, Mississippi, Nebraska, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Tennessee, and Texas. GKF also owns and operates a single-unit Gamma Knife facility in Lima, Peru.

 

The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts.

 

The Company formed the subsidiaries GKPeru and GK Financing U.K., Limited (“GKUK”) for the purposes of expanding its business internationally into Peru and the United Kingdom, respectively; Orlando and LBE to provide proton beam therapy equipment and services in Orlando, Florida and Long Beach, California; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. LBE is not expected to generate revenue within the next two years. GKUK was dissolved in November 2018.

 

The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM through its 50% owned OR21, LLC (“OR21”). The remaining 50% of OR21 is owned by an architectural design company. OR21 is not expected to generate significant revenue within the next two years.

 

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time.

 

All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Note 2 – Accounting Policies

 

Use of estimates in the preparation of financial statements – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of fixed assets and its salvage values, revenues and costs of sales for turn-key and revenue sharing arrangements.  Actual results could differ from those estimates.

 

Advertising costs – The Company expenses advertising costs as incurred. Advertising costs were $113,000, $140,000, and $279,000 during the years ended December 31, 2018, 2017 and 2016, respectively. Advertising costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of operations.

 

F-8

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.

 

Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement, and the minimum cash that must be maintained in Orlando per the subsidiary’s financing agreement.

 

Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.

 

All of the Company’s revenue was provided by eighteen, twenty, and eighteen customers in 2018, 2017, and, 2016, respectively. One customer accounted for approximately 26%, 21%, and 10% of the Company’s total revenue in 2018, 2017, and, 2016, respectively. At December 31, 2018 and 2017, three customers each individually accounted for more than 10% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.

 

All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.

 

Accounts receivable and doubtful accounts – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for probable losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.

 

Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. The Company also presents the consolidated net income and the portion of the consolidated net income and other comprehensive income allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.

 

Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife, IGRT, and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where indicated. Salvage value is based on the estimated fair value of the equipment at the end of its useful life.

 

Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

 

The Company capitalizes interest incurred on property and equipment that is under construction, for which deposits or progress payments have been made. When a rate is not readily available, imputed interest is calculated using the Company’s incremental borrowing rate. The interest capitalized for property and equipment is the portion of interest cost incurred during the acquisition periods that could have been avoided if expenditures for the equipment had not been made. The Company capitalized interest of $115,000, $138,000, and $443,000 in 2018, 2017, and, 2016, respectively, as costs of medical equipment.

 

F-9

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2018, the Company held equipment under operating lease contracts with customers with an original cost of $94,031,000 and accumulated depreciation of $53,716,000. At December 31, 2017, the Company held equipment under operating lease contracts with customers with an original cost of $95,923,000 and accumulated depreciation of $51,403,000.

 

In April 2017, an existing customer exercised their option to purchase the Gamma Knife unit at its hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease terminated in April 2017, at which time, the unit was depreciated to the purchase price of the sale. Based on the guidance provided in Accounting Standards Codification (“ASC”) 360 Property, Plant and Equipment (“ASC 360”), the Company did not classify or measure the asset as held for sale prior to the lease termination, because the Gamma Knife unit was not available for immediate sale.

 

During the year ended December 31, 2018, the Company recorded a receivable of $1,137,000 for insurance coverage related to damage that was incurred on the Company’s PBRT unit. The Company contracted with Mevion Medical Systems, Inc. (“Mevion”), formerly Still River Systems, to repair the damaged unit and incurred repair costs of approximately $977,000, which is included in the Company’s consolidated balance sheet for the year ended December 31, 2018. The Company recorded $185,000 of income from its business interruption insurance for the period the PBRT unit was down undergoing repair. All insurance proceeds and related costs were received and paid subsequent to year-end.

 

Fair value of financial instruments – The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.

 

F-10

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

The estimated fair value of the Company’s assets and liabilities as of December 31, 2018 and 2017 were as follows (in thousands):

 

   Level 1   Level 2   Level 3   Total   Carrying Value 
December 31, 2018                         
Assets:                         
Cash, cash equivalents, restricted cash  $1,792   $       -   $   -   $1,792   $1,792 
Total  $1,792   $-   $-   $1,792   $1,792 
                          
Liabilities                         
Debt obligations  $-   $-   $5,431   $5,431   $5,451 
Total  $-   $-   $5,431   $5,431   $5,451 
                          
December 31, 2017                         
Assets:                         
Cash, cash equivalents, restricted cash  $2,502   $-   $-   $2,502   $2,502 
Total  $2,502   $-   $-   $2,502   $2,502 
                          
Liabilities                         
Debt obligations  $-   $-   $6,082   $6,082   $6,057 
Total  $-   $-   $6,082   $6,082   $6,057 

 

Revenue recognition - The Company recognizes revenues under ASC 840 Leases (“ASC 840”) and ASC 606 Revenue from Contracts with Customers (“ASC 606)”.

 

Rental income from medical services – The Company recognizes revenues under ASC 840 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Revenues from fee per use contracts is determined by each hospital’s contracted rate. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the equipment. Operating costs are determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. For turn-key sites, the Company also shares a percentage of net operating profit. The Company records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the year ended December 31, 2018, the Company recognized revenues of approximately $18,987,000 under ASC 840.

 

Patient income – The Company has a stand-alone facility in Lima, Peru, where a contract exists between GKPeru and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. The Company adopted ASC 606 as of January 1, 2018 using the modified retrospective method. The cumulative effect of adopting ASC 606 did not have a material impact on retained earnings as reported by the Company, and there was no change to the Company’s IT environment following adoption. Accounts receivable earned by GKPeru were not significant for the year ended December 31, 2018. For the year ended December 31, 2018, the Company recognized revenues of approximately $727,000 under ASC 606.

 

Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 for additional information on the Company’s stock-based compensation programs.

 

Costs of revenue – The Company's costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites). Costs of revenues are recognized as incurred.

 

Sales and Marketing – The Company markets its services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development and its Chief Operating Officer. The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services.

 

F-11

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services.

 

Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

 

The Company accounts for uncertainty in income taxes as required by the provisions of ASC 740 Income taxes (“ASC 740”), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.

 

See Note 7 for further discussion on income taxes.

 

Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are initially accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will change its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru under ASC 830 as of December 31, 2018 and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.

 

Asset Retirement Obligations – Based on the guidance provided in ASC 410 Asset Retirement Obligations (“ASC 410”), the Company analyzed its existing lease agreements and determined an asset retirement obligation (“ARO”) exists to remove the respective units at the end of the lease terms. The fair value of the ARO liability is not reasonable to estimate at this time, due to uncertainties about timing, cost and, outcome of the ARO, therefore no liability has been recorded as of December 31, 2018. The Company will re-evaluate this position on a periodic basis when facts and circumstances change that could affect this conclusion.

 

Earnings per share – Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options or warrants.

 

The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2018, 2017 and 2016.

 

   2018   2017   2016 
             
Numerator for basic and diluted earnings per share  $1,023,000   $1,923,000   $930,000 
Denominator:               
Denominator for basic and diluted earnings per share – weighted-average shares   5,836,000    5,754,000    5,570,000 
Effect of dilutive securities Employee stock options and restricted stock   17,000    130,000    13,000 
Denominator for diluted earnings per share – adjusted weighted-average shares   5,853,000    5,884,000    5,583,000 
Earnings per common share- basic  $0.18   $0.33   $0.17 
Earnings per common share- diluted  $0.17   $0.33   $0.17 

 

In 2018, options outstanding to purchase 519,000 shares of common stock at an exercise price range of $2.82 - $3.90 per share and 4,000 restricted stock units were not included in the calculation of diluted earnings per share because they would be anti-dilutive.

 

F-12

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

In 2017, options outstanding to purchase 14,000 shares of common stock at an exercise price of $3.90 per share and 4,000 restricted stock units were not included in the calculation of diluted earnings per share because they would be anti-dilutive.

 

In 2016, options outstanding to purchase 581,000 shares of common stock at an exercise price range of $2.43 - $3.15 per share and 4,000 restricted stock units were not included in the calculation of diluted earnings per share because they would be anti-dilutive.

 

Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company has analyzed its subsidiaries which are all in the business of leasing radiosurgery and radiation therapy equipment to healthcare providers, and concluded there is one reportable segment, Medical Services Revenue. The Company provides Gamma Knife, PBRT, and IGRT equipment to sixteen hospitals in the United States and owns and operates a single-unit facility in Lima, Peru as of December 31, 2018. These seventeen locations operate under different subsidiaries of the Company, but offer the same service, radiosurgery and radiation therapy. The operating results of the subsidiaries are reviewed by the Company’s Chief Executive Officer and Chief Financial Officer, who are also deemed the Company’s Chief Operating Decision Makers (“CODMs”) and this is done in conjunction with all of the subsidiaries and locations.

  

Geographical informationThe Company did not have any international operations as of December 31, 2016, but the Company’s single-unit facility in Peru treated its first patient in July 2017. The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment:

  

   2018   2017   2016 
             
Medical services revenues               
Domestic   96%   99%   100%
Foreign   4%   1%   0%
Total   100%   100%   100%

 

   2018   2017   2016 
Property and equipment, net               
Domestic   93%   93%   93%
Foreign   7%   7%   7%
Total   100%   100%   100%

 

Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. No such impairment has been noted as of December 31, 2018 and 2017.

 

F-13

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued)

 

Accounting pronouncement issued and not yet adopted – In February 2016, the FASB issued ASU No. 2016-02 Leases (“ASU 2016-02”) which requires lessees to recognize, for all leases, at the commencement date, a lease liability, and a right-of-use asset. Under the new guidance, lessor classification criteria for direct financing and sales-type leases is modified. In July 2018, the FASB issued ASU No. 2018-10 Leases (Topic 842) Codification Improvements to Topic 842, Leases (“ASU 2018-10”) and ASU No. 2018-11 Leases (Topic 842) Targeted Improvements (“ASU 2018-11”), in December 2018 the FASB issued ASU No. 2018-20 Leases (Topic 842) Narrow-Scope Improvements (“ASU 2018-20”), and in February 2019 the FASB issued ASU No. 2019-01 Leases (Topic 842) Codification Improvements (“ASU 2019-01”). ASU 2018-11 provides a new transition method in which an entity can initially apply the new lease standards at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This standard is effective for annual periods beginning after December 15, 2018. The new guidance is effective for the Company on January 1, 2019. The Company is evaluating the effect that the ASUs (2016-02, 2018-10, 2018-11, 2018-20, and 2019-01) will have on its consolidated financial statements and related disclosures. Using the modified retrospective transition method, the Company will elect to initially apply the ASUs beginning January 1, 2019 and intends to elect certain other practical expedients upon adoption. The Company performed an analysis to determine if its revenue agreements with customers fall under the scope of ASU 2016-02 or ASU 2014-09 and concluded that, other than with respect to the Company’s stand-alone facility in Lima, Peru, ASU 2016-02 applied. The Company expects adoption of the ASUs will result in the recognition of lease liabilities and right-of-use assets of approximately $1.0M for its operating leases at January 1, 2019, with no initial material impact to its consolidated statements of operations.

 

F-14

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

 

Note 2 – Accounting Policies (continued) 

 

In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires measurement and recognition of expected credit losses for financial assets held. The new guidance is effective for fiscal periods beginning after December 15, 2018. The Company does not expect ASU 2016-13 to have a significant impact on its consolidated financial statements and related disclosures.

 

In February 2018, the FASB issued ASU No. 2018-03 Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2018-03”), which clarifies certain aspects of ASU 2016-01. These are: equity securities without a readily determinable fair value – discontinuation, equity securities without a readily determinable fair value – adjustments, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements to Fair Value Measurement (“ASU 2018-13”), which amended the effective date and other certain measurement aspects of ASU 2018-03. The new guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company does not expect ASU 2018-03 or ASU 2018-13 to have a significant impact on its consolidated financial statements and related disclosures.

 

In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements (“ASU 2018-09”). This standard does not prescribe any new accounting guidance, but instead makes minor improvements and clarifications of several different FASB Accounting Standards Codification areas based on comments and suggestions made by various stakeholders. Certain updates are applicable immediately while others provide for a transition period to adopt as part of the next fiscal year beginning after December 15, 2018. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.

 

Note 3 – Property and Equipment

 

Property and equipment consists of the following:

 

   DECEMBER 31, 
   2018   2017 
         
Medical equipment and facilities  $94,031,000   $95,923,000 
Office equipment   589,000    576,000 
Deposits and construction in progress   3,832,000    1,658,000 
Deposits towards purchase of proton beam systems   2,250,000    2,000,000 
    100,702,000    100,157,000 
Accumulated depreciation   (54,008,000)   (51,666,000)
Net property and equipment  $46,694,000   $48,491,000 

 

The Company has equipment that is secured under capitalized leases, which is included in Medical equipment and facilities, with a total cost of $46,559,000 and associated accumulated depreciation of $20,292,000 as of December 31, 2018 and a total cost of $44,758,000 and associated accumulated depreciation of $16,777,000 as of December 31, 2017. As of December 31, 2018, the Company has one idle Gamma Knife unit with a cumulative net book value of $729,000. There are currently no commitments to place into service or trade in this unit during 2019.

 

As of December 31, 2018, the Company has $3,832,000 in construction in progress. The construction in progress consists of costs associated with the Company’s new Gamma Knife site, which began treating patients in January 2019, deposits payments made for two Cobalt-60 reloads, capitalized and imputed interest, and other costs associated with on-going projects of the Company.

 

F-15

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

Note 3 – Property and Equipment (continued)

 

As of December 31, 2018, the Company has $2,250,000 in deposits toward the purchase of two MEVION S250i PBRT systems from Mevion. The Company has a commitment for the remaining balance for each system. The Company’s first MEVION S250 treated its first patient in April 2016. The Company has entered into a partnership agreement (LBE) with a radiation oncology physician group, which has contributed $400,000 towards the deposits on the third machine. The Company currently does not have customer contracts for the second and third units. The Company reviews the carrying value of these deposits for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value may not be recoverable. The Company has reviewed the deposits, in light of available information, as of December 31, 2018 and has not identified any impairment. See Note 11-Commitments and Contingencies for additional discussion on purchase commitments.

 

Note 4 – Investment in Equity Securities

 

As of December 31, 2018 and 2017 the Company had a $0 investment in the common stock of Mevion. The Company previously accounted for this investment under the cost method. The Company previously carried its investment in Mevion at cost and reviewed it for impairment on a quarterly basis, or as events or circumstances might have indicated that the carrying value of the investment may not be recoverable.

  

Based on guidance provided in ASC 320 Investments–Debt and Equity Securities (“ASC 320”) and Staff Accounting Bulletins (“SAB”) Topic 5M Other Than Temporary Impairment (“OTTI”) of Certain Investments in Equity Securities (“SAB Topic 5M”), the Company analyzed the related events of Mevion, that occurred in the second and third quarters of 2015 and its impact on the Company’s investment. The Company determined that these circumstances indicated a decline in value of its Mevion investment that was other-than-temporary and concluded that a write-down of the carrying value should be recognized. As of June 30, 2015, the Company adjusted its investment in Mevion to the estimated fair value of $600,000 and recorded a $2,114,000 impairment loss. The $2,114,000 other than temporary impairment of its investment in Mevion is recorded in other income (loss) on the Company’s Condensed Consolidated Statement of Operations.

 

During the period ended December 31, 2015, the Company engaged a third-party expert to review and corroborate its assessment of the fair value of the Mevion investment. Based on the third-party analysis, an additional impairment loss of $26,000 was recognized by the Company during the three months ended December 31, 2015. The fair value of the Company’s investment in Mevion, as of December 31, 2015 was approximately $579,000. The impairment loss for the year ended December 31, 2015 was $2,140,000.

 

During the year ended December 31, 2017, the Company reviewed its investment in Mevion and determined the fair value of its investment was $0. Based on the Company’s assessment of its investment in Mevion, the Company recognized an impairment loss for the year then ended December 31, 2017 of $579,000. During 2018, Mevion entered into a merger transaction with Mevion Medical Technology Group Limited, and the Company’s common shares in Mevion were cancelled.

 

Note 5 – Long-Term Debt

 

Long-term debt consists primarily of seven notes with three financing companies collateralized by the Gamma Knife equipment having an aggregate net book value of $13,016,000, the individual customer contracts and related accounts receivable at December 31, 2018. These notes are payable in 36 to 84 fully amortizing monthly installments, mature between December 2019 and March 2026, and are collateralized by the respective Gamma Knife units. The notes accrue interest at fixed annual rates between 4.96% and 6.90%.

 

F-16

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

Note 5 – Long-Term Debt (continued)

 

The following are contractual maturities of long-term debt by year at December 31, 2018:

 

Year ending December 31,  Principal   Interest 
2019  $2,119,000   $276,000 
2020   1,378,000    163,000 
2021   712,000    100,000 
2022   263,000    71,000 
2023   280,000    54,000 
Thereafter   699,000    53,000 
   $5,451,000   $717,000 

 

Note 6 – Obligations Under Capital Leases

 

The Company has eleven capital lease obligations with three financing companies, collateralized by Gamma Knife and PBRT equipment having an aggregate net book value of $26,267,000, the individual customer contracts and related accounts receivable at December 31, 2018. These obligations have imputed interest rates ranging between 4.73% and 13.00%, are payable in 44 to 84 monthly installments, and mature between July 2019 and October 2024. As of December 31, 2017, the Company had twelve capital lease obligations with four financing companies, collateralized by Gamma Knife and PBRT equipment having an aggregate net book value of $27,981,000. At the end of each lease term, the Company has a bargain purchase option to purchase the equipment.

 

Future minimum lease payments, together with the present value of the net minimum lease payments under capital leases at December 31, 2018, are summarized as follows:

 

   Net Present Value 
   of Minimum 
   Lease Payments 
Year ending December 31,     
2019  $5,524,000 
2020   4,017,000 
2021   5,992,000 
2022   970,000 
2023   524,000 
Thereafter   308,000 
Total capital lease payments   17,335,000 
Less imputed interest   2,620,000 
    14,715,000 
Less current portion   4,407,000 
   $10,308,000 

 

F-17

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

Note 7 – Income Taxes

 

As of December 31, 2018, 2017 and 2016 the Company recorded income tax provision expense of $451,000, an income tax provision benefit of $1,103,000, and income tax provision expense of $943,000, respectively. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that is payable over eight years. The Tax Act also establishes new tax laws that will affect 2018 and later years, including, but not limited to, a reduction of the U.S. federal corporate tax rate from 34% to 21%, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, net operating loss deduction limitations, a base erosion, anti-tax abuse tax and a deduction for foreign-derived intangible income and a new provision designed to tax global intangible low-taxed income. As a result of the Tax Act, the Company revalued its federal and state deferred tax liabilities based on a 21% tax rate as opposed to a 34% tax rate. The net effect of this change on the Company’s income tax provision for the year ended December 31, 2017 was a tax benefit of $1,546,000.

 

The increase in the Company’s provision for income taxes as of December 31, 2018 and December 31, 2016 is due to income from the PBRT system and operations of the Company’s subsidiaries. The income tax provision benefit recognized as of December 31, 2017 was due to the Tax Act.

 

The components of the provision for income taxes as of December 31, 2018, 2017 and 2016 consist of the following:

 

   YEARS ENDED DECEMBER 31, 
   2018   2017   2016 
Current:               
Federal  $13,000   $55,000   $24,000 
State   389,000    109,000    146,000 
Total current   402,000    164,000    170,000 
                
Deferred:               
Federal   259,000    (1,335,000)   680,000 
State   (210,000)   68,000    93,000 
Total deferred   49,000    (1,267,000)   773,000 
                
   $451,000   $(1,103,000)  $943,000 

 

F-18

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

Note 7 – Income Taxes (continued)

 

Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2018 and 2017 are as follows:

 

   DECEMBER 31, 
   2018   2017 
Deferred tax liabilities:          
Property and equipment  $(3,566,000)  $(5,009,000)
           
Total deferred tax liabilities   (3,566,000)   (5,009,000)
           
Deferred tax assets:          
Net operating loss carryforwards   80,000    1,421,000 
Accruals and allowances   275,000    157,000 
Tax credits   194,000    438,000 
Other – net   206,000    186,000 
Capital loss carryover   948,000    959,000 
           
Total deferred tax assets   1,703,000    3,161,000 
           
Valuation allowance   (1,096,000)   (1,062,000)
           
Deferred tax assets net of valuation allowance   607,000    2,099,000 
           
Net deferred tax liabilities  $(2,959,000)  $(2,910,000)

 

These amounts are presented in the financial statements as follows:

 

   DECEMBER 31, 
   2018   2017 
         
Deferred income taxes (non-current)  $(2,959,000)  $(2,910,000)
   $(2,959,000)  $(2,910,000)

 

The (benefit) provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2018, and 34% in 2017 and 2016) to income before taxes as follows:

 

F-19

 

 

American Shared Hospital Services

Notes to Consolidated Financial Statements

 

Note 7 – Income Taxes (continued)

 

   YEARS ENDED DECEMBER 31, 
   2018   2017   2016 
             
Computed expected federal income tax  $313,000   $279,000   $637,000 
State income taxes, net of federal benefit   125,000    28,000    169,000 
Non-deductible expenses   (12,000)    41,000    42,000 
Impact of US Tax Reform   -    (1,546,000)   - 
Change in valuation allowance   34,000    180,000    25,000 
Other   (9,000)    (85,000)   70,000 
                
   $451,000   $(1,103,000)  $943,000 

 

On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the U.S. tax code including, but not limited to, requiring a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that is payable over eight years (the "Transition Tax"), a reduction of the U.S. federal corporate tax rate from 34% to 21%, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, net operating loss deduction limitations, a base erosion, anti-tax abuse tax (“BEAT”) and a deduction for foreign-derived intangible income (“FDII”) and a new provision designed to tax global intangible low-taxed income ("GILTI").

 

In December 2017, the SEC staff issued SAB No. 118 (“SAB 118”) which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740 Income taxes (“ASC 740”). In accordance with SAB 118 a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. Additional work is necessary for a more detailed analysis of our deferred tax assets and liabilities. Any subsequent adjustment to these amounts would be recorded to current tax expense in the quarter of 2018 when the analysis was complete. We included a provisional estimate in the financial statements for the period ended December 31, 2017, as our accounting for the Tax Act under ASC 740 was not completed. As of December 31, 2018, the Company completed its analysis of the income tax effects of the Tax Act and there was no material impact to the Company’s consolidated financial statements.

 

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. On December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.

 

The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our Company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.

 

At December 31, 2018, the Company is expected to utilize the remainder of its net operating loss carryforward for federal income tax return purposes. The Company has net operating loss carryforwards for state income tax purposes of approximately $636,000 that begin to